 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 1 of 63 
  
 
 
 
CLINICAL STUDY PROTOCOL  
 
 
FAVIPIRAVIR in COVID -19 
Effect on viral shedding and disease progression  
 
 
The Prevent Severe COVID-19 (PRESECO ) Study  
 
  
Protocol Number: ATI0220  
 
Protocol Version: 5.1 
Date: 02 November 2021 
 
 
SPONSOR:  
Appili Therapeutics Inc.  
21-1344 Summer St, Halifax, NS, B3H 0A8, Canada  
Tel #: +1 902 442 4655  
Web: www.appilitherapeutics.com  
 
 
 
 
 
 
 
This confidential clinical study protocol is the property of Appili Therapeutics Inc. No unp ublished 
information contained herein may be disclosed without prior written approval of Appil i Therapeutics Inc.  
  

 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 2 of 63 
  
Signatures of Approval of Protocol  
 
This protocol was subject to critical review and has been approved by the following persons:  
 
Affiliation:  
 
 
 
Sponsor:   Prasann Bavaniya     
 Name  Signature & Date  
 
 
 
Medical expert:  Dr. Yoav Golan                                                                            
 Name  Signature & Date  
 
Sponsor:  Appili Therapeutics Inc.  
   21- 1344 Summer St, Halifax, NS, B3H 0A8, Canada  
   Phone: +1 902 442 4655  
Web: www.appilitherapeutics.com  
  
Sponsor contact:  Prasann Bavaniya  
   Senior Clinical Project Manager  
   Appili Therapeutics Inc.  
   Phone: +1 902 442 4655 ext. 7, 5  
   Cell: +1 647 336 0077  
   E- mail: pbavaniya@appilitherapeutics.com    
  
Medical expert:  Dr. Yoav Golan  
   Chief Medical Officer  
   Appili Therapeutics Inc.  
   Phone: +1 617 240 6666  
   E- mail: ygolan@appilitherapeutics.com   
 
 
  
03-Nov-2021
Yoav Golan (Nov 3, 2021 23:35 EDT)Nov 3, 2021
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 3 of 63 TABLE OF CONTENTS  
1.0 STATEMENT  OF COMPLIANCE  .............................................................................................................................  5 
2.0 PROTOCOL  SUMMARY  ..........................................................................................................................................  7 
2.1 Protocol Synopsis ...................................................................................................................................................  7 
2.2 Scheme  ................................................................................................................................................................  14 
2.3 Schedule of Activities (SoA)  ..................................................................................................................................  15 
3.0 INTRODUCTION  ....................................................................................................................................................  18 
3.1 Study Ration ale ....................................................................................................................................................  18 
3.2 Favipiravir: The study drug  ..................................................................................................................................  18 
3.3 Favipiravir: Risk/Benefit Assessment  ....................................................................................................................  20 
4.0 OBJECTIVES  AND  ENDPOINTS  ...........................................................................................................................  20 
5.0 STUDY  DESIGN  .....................................................................................................................................................  24 
5.1 Overall Design  .....................................................................................................................................................  24 
5.2 Scientific Rationale for Study Design  ....................................................................................................................  24 
5.3 Dose Justification and Tablets needed  ..................................................................................................................  24 
5.4 Dosing in Special Populations  ..............................................................................................................................  25 
5.5 Storage and Stability  ............................................................................................................................................  25 
5.6 Study Drug Dispensation  ......................................................................................................................................  26 
5.7 Expected Side Effects  ...........................................................................................................................................  26 
5.8 Additional Safety Considerations  ..........................................................................................................................  26 
5.9 End of Study Definition  ........................................................................................................................................  27 
6.0 STUDY  POPULATION  ...........................................................................................................................................  28 
6.1 Inclusion Criteria  .................................................................................................................................................  28 
6.2 Exclusion Criteria  ................................................................................................................................................  29 
6.3 Lifest yle Considerations  .......................................................................................................................................  30 
6.4 Screen Failures  ....................................................................................................................................................  30 
6.5 Strategies for Recruitment and Retention  ..............................................................................................................  30 
7.0 STUDY  INTERVENTIONS  .....................................................................................................................................  31 
7.1 Study Intervention(s) Administration .....................................................................................................................  31 
7.2 Preparation/Handling/Storage/Accountability  ......................................................................................................  32 
7.3 Measures to Minimize Bias: Randomization and Blinding  .....................................................................................  33 
7.4 Study Intervention Compliance  .............................................................................................................................  34 
7.5 Concomitant Therapy  ...........................................................................................................................................  34 
7.6 Teleme dicine  ........................................................................................................................................................  35 
7.7 Viral Shedding Testing  .........................................................................................................................................  35 
8.0 STUDY  INTERVENTION  DISCONTINUATION  AND  SUBJECT  WITHDRAWAL/  DISCONTINUATION  ..........  37 
8.1 Discontinuation of Study Intervention  ...................................................................................................................  37 
8.2 Subject Discontinuation/Withdrawal from the Study ..............................................................................................  38 
8.3 Lost to Follow -Up ................................................................................................................................................  38 
9.0 STUDY  ASSESSMENTS  AND  PROCEDUR ES ......................................................................................................  39 
9.1 Efficacy Assessments  ............................................................................................................................................  39 
9.2 Study Procedures  .................................................................................................................................................  39 
9.3 Adverse Events and Serious Adverse Events  ..........................................................................................................  42 
9.4 Adverse Event Reporting  ......................................................................................................................................  44 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 4 of 63 9.5 Unanticipated Problems (UPs)  .............................................................................................................................  45 
10.0  STATISTICAL  CONSIDERATIONS  .....................................................................................................................  46 
10.1 Statistical Hypotheses  .........................................................................................................................................  46 
10.2 Sample Size Considerations  ................................................................................................................................  46 
10.3 Populations for Analyses  ....................................................................................................................................  48 
10.4 Statistical Analyses: General Approach  ..............................................................................................................  48 
10.5 Analysis of the Primary Efficacy Endpoint(s)  ......................................................................................................  49 
10.6 Analysis of the Key Secondary Endpoint(s)  .........................................................................................................  49 
10.6.1  ADDITIONAL SECONDARY EFFICACY ANALYSIS  ....................................................................................................  49 
10.7 Safety Analyses  ..................................................................................................................................................  50 
10.8 Other prespecified analyses  ................................................................................................................................  50 
10.9 Exploratory Analyses  .........................................................................................................................................  51 
11.0  SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  ...............................................  51 
11.1 Regulatory, Ethical, and Study Oversight Considerations.  ...................................................................................  51 
11.2 Clinical Monitoring  ............................................................................................................................................  54 
11.3 Data Handling and Record Keeping  ...................................................................................................................  55 
11.4 Protocol Deviations ............................................................................................................................................  55 
11.5 Publication and Data Sharing Policy  ..................................................................................................................  56 
11.6 Conflict of Interest Policy  ...................................................................................................................................  56 
11.7 Additional Considerations  ..................................................................................................................................  56 
12.0  ABBREVIATIONS ......................................................................................................................................................  56 
13.0  PROTOCOL AMENDMENT HISTORY  ...........................................................................................................................  59 
14.0  REFERENCES  .......................................................................................................................................................  61 
 
  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 5 of 63 1.0 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonization  Good Clinical 
Practice ( ICH GCP) and the following  and any other applicable local regulatory bodies :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical s tudies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
• Brazilian National Health Surveillance Agency ( Agência Nacional de Vigilância Sanitária 
(ANVISA)  Regulations applicable to clinical studies ( Law No.782, Resolution No .9, Resolution  
No.61 and Resolution  No.176) 
 
Clinical trial staff who are responsible for the conduct, management, or overs ight of this study  should 
have completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all subject  materials will be submitted 
to the appropriate Institutional Review Board /Independent Ethics Committee (IRB/IEC) for review and 
approval.   Approval of both the protocol and the consent form must be obtained before any subject  is 
enrolled. Any amendment to the protocol will require review and approval by the IRB /IEC  before the 
changes are implemented to the study.  In addition, all changes to the consent form will  be IRB /IEC -
approved; a determination will be made regarding whether  a new consent needs to be obtained from 
subject s who provided consent , using a previously approved consent form . 
 
  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 6 of 63  
INVESTIGATOR’S STATEMENT 
 
Study title: “Double -blinded, placebo control, randomized, phase -3 clinical trial to evaluate clinical efficacy of 
Favipiravir in patients with mild to moderate symptoms related to COVID -19 infection”  
 
The signature below:  
 
• Confirms my agreement to conduct the trial in compliance with Good Clinical Practice (G CP), 
applicable regulatory, and the clinical study protoco l requirements,  
 
• Confirms my agreement to comply with the procedures for data recording and reporting,  
 
• Confirms my agreement to permit monitoring, auditing and regulatory inspections,  
 
• Confirms my agreement to retain the study essential documents in investigator file u ntil Appili 
Therapeutics informs me these documents are no longer needed (e.g. over 15 years) , 
 
• Ensure all the persons assisting with the study are adequately informed about protocol, t he 
investiga tional product(s), and their trial rel ated duties and functions,  
 
• Confirms that I have read this protocol and I agree to comply with all parts or item s. 
 
All information regarding this protocol and the investigational product(s) w ill be treated as strictly 
confidential.  
 
Trial site name and full address:  
 
 
 
 
 
 
 
 
Principal Investigator ’s Name:  
 
 
 
 
 
____________________________ 
Signature with date  
 
  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 7 of 63 2.0 PROTOCOL SU MMARY  
2.1 Protocol Synopsi s 
Long  Title  Double- blinded, placebo control, randomized , phase -3 clinical trial to evaluate clinical 
efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID -19 
infection  
Short title  Favipiravir to shorten the time to sustained clinical recovery  
Protocol No. ATI0220 
Version  5.1 d ated 02-November-2021 
Background  COVID -19 starts as a pure viral infection and evolves into a multifactorial disease w ith 
components of hyper immune activation, end organ damage, and fibrosis. Suppression of 
viral replication is expected to be impactful e arly in the course of disease.  The ability to 
mitigate the symptoms at an early stage will prevent progression to severe COVID -19 and 
can save many lives. Early treatment could also reduce viral shedding, diminishing t he 
period of infectivity and decreasing the number of secondary cases.  
Study 
design  Double- blinded, placebo controlled, randomized, phase 3 trial evaluating the antiviral 
drug favipiravir as potential therapy for mild to moderate COVID -19 in adult outpatients 
who are not requiring hospitalization and who had a positive COVID -19 test withi n 72 
hours of study enrollment.  Mild to moderate symptoms are defined as:  O2 Saturation 
>94%, no requirement of supplemental O 2, lack of known sepsis or organ failure. Subjects 
will be randomly assigned to favipiravir (the first two doses are 1800 mg given 
approximately 12 hours apart , followed by 800mg approximately every 12 hours  to 
complete  10 days of therapy ) or placebo.  
Favipiravir A selective inhibitor of viral RNA -dependent RNA polymerase (RdRP) with potent 
antiv iral activity against single -stranded RNA viruses including coronaviruses. It is 
indicated in the treatment of influenza in Japan and  China and COVID -19 in Russia and 
India. 
Sample size  The entire study: approximately 1250 (approximately 625 subjects  per treatment arm ) are 
estimated to be sufficient  to get 815  sustained  clinical recoveries.    
The viral shedding sub -study: approximately 550 (approximately 275 per arm) to obtain 
112 viral shedding events . 
Primary 
Study 
Objective  • Demonstrate that treatment with favipiravir for COVID -19 patients with mild to 
moderate symptoms will shorten the time to sustained clinical recovery (‘clinical 
endpoint component’)  compared to placebo .   
Study 
Secondary 
Objective  • Demonstrate that treatme nt with favipiravir will shorten the period of viral shedding 
(‘viral shedding component’)  compared to placebo   
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 8 of 63 • Demonstrate that treatment with favipiravir will reduce the proportion of subje cts with 
COVID -19 related hospitalizations or emergency departmen t visits compared to 
placebo   
• Demonstrate that treatment with favipiravir will reduce the proportion of subje cts with 
COVID -19 related hospitalizations or emergency department  visits or the 
development of two or more new COVID -19 related symptoms compared to placebo   
Endpoints  
 
 
 Symp tom Assessment:  
A patient -reported outcome (PRO)  instrument will be used to assess COVID -19-related 
symptoms (measuring signs and symptoms best known by the patient and measured from 
the patient perspective). The assessment will be performed every 24 hours at 
approximately the same time each day .  The following symptoms will be included in the 
daily assessment ( regardless of which symptoms the subject had at baseline, as new 
symptoms may appear following the baseline assessment ):  
a. Stuffy or runny nose, sore throat,  shortness of breath, cough, lack of energy 
or tiredness, muscle or body aches, headache, chills or shivering, feeling hot 
or fever ish, nausea : subjects rate symptom at its worst over a 24 -hour period 
using a 4 -point scale for severity - 0=none, 1=mild, 2=moderate, 3=severe  
b. Vomitin g, diarrhea: subjects rate symptom frequency over a 24 -hour period 
using a 4 -point scale for frequency - 0= not at all, 1=1 –2 times, 2=3 –4 times, 
3=5 or more times  
c. Sense of taste, sense of smell  (not included in the Primary Endpoint 
assessment) : subjects rate symp tom over a 24 -hour period using a 3 -point 
scale - 0= sense (of smell or taste) is the same as usual, 1= sense is less than 
usual, 2=have no sense  
Primary Efficacy Endpoint:  
Time to Sustained C linical Recovery defined as number of days from start of study 
treatment to Sustained Alleviation of Symptoms , evaluated from study day 1 onward . The 
endpoint will be considered to have been met at the earliest time point, starting on study 
day 1, at which the subj ect has reached Sustained Alleviation of Symptoms as defined by: 
(1) Blood oxygen saturation >94% on room air at rest , (2) Oral  temperature <38.0  ºC AND  
(3) All COVID -19 associated symptoms (stuffy or runn y nose, feeling hot or feverish, 
chills or shivering, cough, sore throat, lack of energy or tiredness , nausea, headache, 
muscle or body aches, shortness of breath, vomiting, diarrhea) (Symptoms related to smell 
or taste are not included in the primary endpoint) reported by the patient have reached a 
severity of “0 – none” or “1 – mild” in assessments for 4 -point scale assessments and not 
known to have redeveloped any COVID -19 associated signs and symptoms (not including 
reduced sense of taste or smell) in a severity beyond mild  for 4 consecutive days (inclusive 
of the day when  clinical recovery  was achieved ) when  assessed from the start of study 
treatment to day 28. To meet the primary endpoint, subjects must survive with no 
hospitalization to day 28.  
Key Secondary Efficacy Endpoint:   
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 9 of 63 • Proportion of subjects with COVID -19 progression, where progression is defined  
as the occurrence from study day 1 onward of any emergency department (ED) 
visit for COVID -19 worsening or shortness of breath OR hospitalization for 
COVID -19 worsening or shortness of breath OR death  (narrow progression)  
 
• Proportion of subjects with COVI D-19 progression, defined as the occurrence 
from study day 1 onward of any ED visit for COVID worsening or shortness of 
breath OR hospitalization for COVID worsening or shortness of breath OR death 
OR the development of symptomatic worsening from study day 1 onward (defined 
as >2 additional COVID symptoms at a level  of moderate or severe which have 
not existed (at any level of severity) at baseline  or fever (temperature of ≥38.0ºC) 
which has not existed at baseline  or oxygen desaturation (O2 saturation <94%) 
which has not existed at baseline ) (Broad progression).  
 
• Viral Shedding Sub -Study: 
Time (number of days) to conversion (defined as undetectable viral load ) of 
detectable SARS -CoV -2 viral RNA in RT -PCR assays of saliva, from start of 
study treatment to date of last viral assessment . Included: all subjects with a 
positive PCR on study day 1  or 2 or 3 . The endpoint will be assessed from study 
day 1 onward. 
Additional Secondary Efficacy Endpoints  
Time (number of days) to negative conversion of positive SARS -CoV -2 viral culture 
assays of saliva, from start of study treatment to date of last viral assessme nt. Subjects 
with a positive saliva SARS -CoV -2 PCR on any study day will have viral cultures 
performed. Subjects with a positive viral culture on day 1  or 2 or 3  will be included 
in this analysis.  The endpoint will be assessed from study day 1 onward. 
Expl oratory Endpoints:  
• Proportion of subjects showing sustained clinical recovery by study Day 1, 3, 5, 7, 
10, 14, 21.  
• Proportion of subjects showing resolution of symptoms by Days 1, 3, 5, 7, 10 , 14, 
21, where resolution is defined as symptom severity of 0 f or all symptoms as well 
as temperature of <38.0  ºC as well as oxygen saturation of ≥94%.  
• Proportion of patients showing negative conversion of detectable SARS -CoV -2 
viral RNA (defined as SARS -CoV -2 viral load conversion from detectable  on 
study day 1 or 2  or 3 to undetectable  thereafter) in saliva on Study Days 3, 5, 7 and 
10. Included: all su bjects with a positive PCR (defined as detectable viral load ) on 
study day 1  or 2 or 3 . 
• Proportion of patients showing negative conversion of positive SARS -CoV -2 viral 
culture in saliva on Study Days 3, 5, 7, and 10. Subjects with a positive saliva 
SARS -CoV-2 PCR on any study day will have viral cultures performed. Subjects 
with a positive viral culture on day 1 or 2 or 3 will be included in this analysis.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 10 of 63 • Proportion of subjects dying from any cause over an assessment period from start 
of study treatment until Day 28.  
• Proportion of subjects requiring mechanical ventilation  over an assessment period 
from start of study treatment until Day 28.  
• Time (number of days) to negative conversion (defined as viral load <100 copies ) 
of detectable SARS -CoV -2 viral RNA (defined as viral load >100 copies ) in RT -
PCR assays of saliva, from start of study treatment to study day 10. Included: al l 
subjects with a positive PCR on study day 1 or 2 or 3. The endpoint will be 
assessed from study day 3 onward. 
• Time to Sustained Clinical Recovery defined as number of days from start of study 
treatment to Sustained Alleviation of Symptoms , evaluated from study day 3 
onward. 
• Proportion of subject with COVID -19 progression, where progression is defined 
as the occurrence at any point from study day 1 to study day 28 of emergency 
department (ED) visit for any reason OR hospitalization for any reas on. 
• Proportion of subjects with COVID -19 progression, where progression is defined 
as the occurrence from study day 3 onward of any emergency department (ED) 
visit for COVID -19 worsening or shortness of breath OR hospitalization for 
COVID -19 worsening or shortness of breath OR death  (narrow progression)  
 
• Proportion of subjects with COVID -19 progression, defined as the occurrence 
from study day 3 onward of any ED visit for COVID worsening or shortness of 
breath OR hospitalization for COVID worsening or shortness of breath OR death 
OR the development of symptomatic worsening from study day 3 onward (defined 
as >2 additional COVID symptoms at a level of moderate or severe which have 
not existed (at any level of severity) at baseline  or fever (temperature of ≥38.0 ºC) 
which has not existed at baseline  or oxygen desaturation (O2 saturation <94%) 
which has not existed at baseline ) (Broad progression).  
Safety endpoint:  
• Number (and proportion) of patients reporting treatment emergent adverse events 
(TEAEs) (by MedDRA system organ class and preferred term) . 
• Number (a nd proportion) of patients reporting serious treatment emergent adverse 
events (TEAEs) (by MedDRA system organ class and preferred term).  
• Vital Signs including oral temperature, heart rate, oxygen s aturation with height 
and weight.  
• Clinical laboratory tests including Biomarkers, Chemistry, Coagulation and 
Hematology.  
Study 
duration  • Individual subject will complete all the study visits within 2 8 days of enrollment.   
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 11 of 63 • Adverse events will be monitored and collected by the Study Team from the point of 
signed consent until study day 2 8. 
Study sites/  
facilities  • COVID -19 testing centers  
• COVID -19 testing laboratories  
• Clinic /Hospital/Treatment Centre/Research Cent er 
• Subjects’ home  
• Besides study visits on Day 1 and Day 10 which will be in -person in-study site or at 
the subject’s home , all other s tudy procedures do not require  in-person interaction and 
will be done remotely , using telehealth and video conferencing. Study materials will 
be provided to the subject at the s tudy site or at the subjects ’ home . 
Enrollment 
strategy  • Study candidates will be identified at COVID testing centers, COVID  testing 
laboratories , and in other clinical care settings.  
• Tested individuals who are >18 years will be asked  at the testing center or at the time 
of receiving a positive test result or when seen at a care center for suspected or 
confirmed COVID -19 for a verbal consent to be approached by the study team.  
• Study team member will inform  study candidates  about the stu dy and probe their 
interest in participating. If interested, study subjects will be screened for  inclusion and 
exclusion criteria. If qualified for enrollment, an in -person visit will be scheduled . 
• Enrollment of subjects age 18 -30 without underlying medica l conditions will be 
capped at 40% 
• The viral shedding sub -study will include approximately 550 subjects to be enrolled 
into the trial  
Inclusion 
criteria  Study subjects should meet all of the following criteria:  
1. Adults age 18 or older  
2. Tested positive for SARS -CoV -2 by RT -PCR assay or by Rapid Antigen assay 
(first positive test) using a respiratory tract sample (either nasopharyngeal swab 
OR oropharyngeal swab OR nasal aspirate OR tracheobronchial aspirate OR 
saliva) collected within 72 hours of randomization  
3. Stated willingness to give their written informed consent to participate in the study  
4. Stated willingness to comply with all study procedures and availability for the 
duration of the study  
5. Males must be sterile, OR agree not to donate semen AND agree to strictly adhere 
to contraceptive measures (e.g. condom use) during the study and for 7 days 
following the last dose of study medication  
6. Females must be unable to bear children, OR ensure that their male partner is 
incapable of fatherin g a child, OR, if of childbearing potential will strictly adhere 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 12 of 63 to contraceptive measures during the study and for seven days following the last 
dose of study medication  (as detailed in section 5.8)  
7. Females must agree to stop breast -feeding prior to first  dose of study drug and 
through seven days after completing therapy  
8. Females must have a negative pregnancy test at screening  
9. Ability to take oral medication and be willing to adhere to the favipiravir/placebo 
regimen  
10. Minimal baseline severity score for COV ID-19-related symptoms: at least two 
symptoms with a score of 2 or higher. COVID -19-related symptoms include: 
Stuffy or runny nose, sore throat, shortness of breath, cough, lack of  energy or 
tiredness, muscle or body aches, headache, chills or shivering, f eeling hot or 
feverish , nausea, diarrhea, vomiting (Excluding changes in the sense of taste or 
smell )  
11. Subject has access to a smart phone , tablet or PC  
Exclusion 
Criteria  An individual who meets any of the following criteria will be excluded from participation 
in this study:  
1. O2 saturation <94%  
2. Shortness of breath at rest  
3. Heart rate ≥ 125 per minute  
4. COVID -19 symptoms first presented >5 days prior to randomization  
5. Requirement for hospitalization at the time of enrollment  
6. Participation in another trial or use of any experimental treatment for COVID -19 
7. Treatment with high steroid dose  i.e. >30 mg/day  prednisolone equivalent  
(excluding stable chronic treatment) or remdesivir  or anyone receiving SARS -
CoV -2 monoclonal antibodies within 3 months  prior to enrollment  
8. Known  sepsis or organ dysfunction/ failure  
9. Known infection with a respiratory virus other than SARS -CoV2 (e.g. Influenza) 
or any known bacterial infection (affecting the respiratory system or any other 
system)  
10. Inability to adhere to st udy requirements  
11. For premenopausal women: unwilling or unable to use effective birth control 
measures  
12. Known allergy to favipiravir  
13. Known end -stage kidney disease or requiring hemodialysis or continuous 
ambulatory peritoneal dialysis (CAPD)  
14. Known liver impairment greater than Child -Pugh A  
15. Psychiatric illness that is not well controlled (defined as stable on a regimen for 
more than one year).  
16. Known  elevated uric acid  levels in the past year or taking uric acid lowering 
medications (allopurinol, febuxostat)  
17. History of hereditary xanthinuria or history of xanthine urolithiasis.  
18. History of gout or actively being treated for gout.   
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 13 of 63 19. Current use of the following medications, which cannot be discontinued for the 
duration of the study: pyrazinamide, hydralazine, mor e than 3000 mg of 
acetaminophen per day.  
Study 
evaluations  Subjects will be followed for symptoms and signs of infection (until study day 2 8), 
adverse events (any AEs: until study day 14, SAEs: until study day 2 8), and viral shedding 
(daily from study day 1 to 10).   
Statistical 
plan  • The primary analysis population is the mITT population , which includes all 
randomized subjects who took at least 1 dose of study drug  (excluding subjects who 
qualified for enrollment  solely based on changes in smell or taste) .  For the primary 
efficacy endpoint of time to sustained clinical recovery, group sample sizes of 
approximately 625 subjects in each treatment arm (favipiravir and placebo) will 
achieve sufficient power to demons trate a clinically meaningful difference using a 
two-sided Wilcoxon test at a n overall  significance level of 0.0 5.  
• An interim analysis will be performed to a ssess the safety of the patients, the efficacy 
endpoint for futility, the efficacy endpoint for treatment effect, and the progress of the 
trial and any medical consideration required to support patient’s health and safe ty.  
The nominal alpha of 0.02 and of 0.0369,  at the time of interim an d final analysis, 
respec tively. A p -value less than 0.02 (interim) or 0.0369  (final) will be considered to 
be statistically significant . Futility will be concluded at interim on the primary efficacy 
endpoint if Z-value is smaller than 0.58964 (i.e. p-value is larger than 0.6389).  
• For the viral shedding endpoint of time to undetectable viral shedding, group sample 
sizes of 275 subjects in each treatment arm will have sufficient  power to detect a 
substantial effect size using a two-sided Wilcoxon test at a significance level of 0.05 .  
  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 14 of 63 2.2 Scheme  
 
  
Screening and  
Baseline  
Assessment  
(Day 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Days 1  to 10  
 
 
 
 
 
 
 
Hospitalized  
Final Post  
Treatment  
Visit  
Non-Hospitalized  
 
 
 
 
 
 
 
 
 
 
 
 Total N = 1250 :  Screen potential subjects by inclusion and exclusion criteria; 
obtain informed consent. obtain history, document. Perform baseline assessments , 
record SARS -Co-V test result, confirm subject meets all inclusion and no 
exclusion criteria, randomize in IWRS/ EDC prior to treatment  
 
Randomize in IWRS ,  
Provide blinded IP kit (Favipiravir or placebo) and other study materials  
Refer to Section of Schedule of Activities   
Follow- up assessments of study endpoints and safety.  
Refer to Section of Schedule of Activities  
Saliva sample (for Viral shedding ) collection : daily from study day 1 to 10 
Saliva sample shipment to laboratory: on day 5 +1 and day 10+1  
Final Assessments  
Refer to Section of Schedule of 
Activities   
Arm 2  
placebo  
N=625 Arm 1  
favipiravir 
N=625 
  
Randomize 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 15 of 63 2.3 S chedule of Activities (SoA)   
 
 
 
Key activities 1  
 
 
Performed  
By 
Screening & Baseline / 
Randomization / 
Treatment Day 1  
Treatment Day 2  
Treatment Day 3  
Treatment Day 4  
Treatment Day 5  
Treatment Day 6  
Treatment Day 7  
Treatment Day 8  
Treatment Day 9  
Treatment  Day 10   
Post-Treatment Day 1 
Post Treatment Day 2  
Post-Treatment Day 3  
Post-Treatment Day 4 
Post-Treatment Day s 5 to 6  
Post-Treatment Day 7 
Post-Treatment Day s 8-10 
Post-Treatment Day 11 
Post-Treatment Day s 12-13 
Post-Treatment Day  14 
Post-Treatment Day s 15-17 
Post-Treatment Day 18  
Early Termination or 
Hospitalization  
STUDY DAY   
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
-
16 17 18 
- 
20 21 22 
- 
23 24 25 
- 
27 28  
Informed Consent  Study Team  X                       
Confirmation of having a 
positive SARS -CoV2 test  Study Team  X                       
Record demographics (age, 
race, ethnicity, gender)  Study Team  X                       
Register in IWRS to allot 
subject screen number  Study Team  X                       
Review past medical and 
surgical history  Study Team  X                       
Record smoking, alcohol, 
medication history  Study Team  X                       
Record height and weight  Study Team  X11                       
Assess Inclusion/ Exclusion 
Criteria Study Team  X                       
Randomization through IWRS 
to allot blinded IP kit number 
and also to assign 
randomization number  Study Team  X             
          
Create ePRO credentials for 
the subject and help set -up the 
mobile app in subject’s device  Study Team  X9             
          
Blood tests 2 Study Team  X         X              
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 16 of 63  
 
 
Key activities 1  
 
 
Performed  
By 
Screening & 
Baseline / 
Randomization / 
Treatment Day 1  
Treatment Day 2  
Treatment Day 3  
Treatment Day 4  
Treatment Day 5  
Treatment Day 6  
Treatment Day 7  
Treatment Day 8  
Treatment Day 9  
Treatment  Day 10   
Post-Treatment Day 
1 
Post-Treatment Day 
2 
Post Treatment Day 
3 
Post-Treatment Day 
4 
Post-Treatment 
Days 5 to 6  
Post-Treatment Day 
7 
Post-Treatment 
Days 8-10 
Post-Treatment Day 
11 
Post-Treatment 
Days 12-13 
Post-Treatment Day  
14 
Post-Treatment 
Days 15-17 
Post-Treatment Day 
18 
Early Termination 
or Hospitalization  
STUDY DAY   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15-
16 17 18- 
20 21 22- 
23 24 25-
27 28  
Perform Urine Pregnancy Test 
for pre -menopausal women only 
(women of childbearing 
potential) and report Subject X9      X       
        X X 
Provide allotted Investigational 
product (IP) (favipiravir or 
Placebo) to subject   
Study Team  X             
          
Administration of IP 
(Favipiravir/Placebo) and report 
3  Subject X9 X X X X X X X X X    
          
Report Concomitant 
Medications including OTC and 
herbal products Subject X X X X X X X X X X X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 
Assess Concomitant 
Medications including OTC and 
herbal products5 Study Team  X  X  X  X  X X    
X  X  X  
X  
X X 
Assessment of IP adherence5 Study Team  X X X X X X X X X X    
           
Report COVID -19 signs and 
symptoms 4 Subject X9 X X X X X X X X X X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 
Review and Assess COVID -19 
signs and symptoms 5 Study Team  X  X  X  X  X X    X  X  X  X  X X  
Assess and report AE 5 Study Team  X  X  X  X  X X    X  X  X  X  X X 
Measure and report O2 
saturation, heart rate and oral 
temperature 5, 6 Subject X9 X X X X X X X X X X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 X10 
Viral specimen (Saliva) 
collection and storage at 
subject’s residence in room 
temperature 7 Subject X9 X X X X X X X X X    
        
  
Viral specimens (Saliva) 
shipment from subject’s 
residence to  laboratory 8  
Courier      
X      
X    
        
  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 17 of 63  
1 If clinical evaluation is deemed not feasible due to subject’s condition, the  study team to collect Early Termination Visit data  and attempt to complete the 21 -day and 28 -
day follow -up call and AE assessment for those subjects who are hospit alized and deemed off study . 
 
2 CBC  with differential , Electrolytes, BUN, Creatinine, Random Blood Serum Glucose, AST, ALT, Bilirubin, uric acid, SARS -CoV2 IgG, IL -6, IL -10, ESR, CRP, D -
Dimer, ferritin. (CRP = C -reactive protein, IL -6 = Interleukin -6, IL -10 = Interleukin- 10, CBC = Complete Blood Count). Site do not require to wait for blood test result to  
randomize subjects. For day 10 blood test , ±1 day window period is acceptable.    
 
3 The first two doses are 1800 mg taken  approximately 12 hours apart, followed by 800  mg taken  approximately every 12 hours to complete 10 days of therapy .  
 
4 During screening, record the number of days since the onset of COVID -19 symptoms  
 
5 The study team will be reviewing the data reported by subject to ensure compliance , accuracy and completeness on days 1, 3, 5 , 7, 9, 10, 14, 17, 21, 24, and 28.  Beyond 
Study Day 10, once the subject meets the primary efficacy endpoint, the subject is not r equired to continue the self -assessment and reporting of COVID -19 symptoms. 
However, the study team, during the remote patient visits will evalua te and report the severity of COVID -19 associated symptoms as per the set frequency mentioned in 
the table.  
 
6 Collect oximetry data  once daily, with the caveat that if the daily O2 saturation result is 90 -93%, the subject will repeat the measurement 2 hours later. If the result i s 
<90%, the subject is instructed to contact the study team. The study team will decid e if a recheck in 2 hours is appropriate or the subject needs further medical eval uation.  
Oral temperature will be measured twice daily.  Heart rate will be measured once daily.  
 
7 Until the sub -study enrollment is completed, all subjects will be enrolled into the viral shedding s ub-study. However, If they choose so, subjects can opt -out of 
participating in the viral shedding sub -study.  
 
8 1st shipment on day 5 (+1) for all samples  collected and 2nd shipment on day 10 (+1) for all the remaining  collected samples. Saliva samples of 2nd shipment can be  
hand ed-over to site staff during  the in-person site visit on day  10 (Site staff to ship it to laboratory).  
 
9 Activity to be performed  at site with the help of site staff to ensure that the subjects are  comfortable to perform at home by themselves from next day onwards.  
 
10 Beyond Study Day 10, once the subject meets the primary efficacy endpoint, the s ubject is not required to continue the self -assessment and reporting of COVID -19 
symptoms  and vitals. However, the study team, during the remote patient visits wi ll evaluate and report the severity of COVID -19 associated symptoms and vitals as per 
the set frequency mentioned in the  table. Data will be entered into ePRO from Day 1 to Day 10 irrespective of whether sustai ned clinical recovery is met or not.  
 
11 Height and weight should be collected at the screening visit.  In cases whe re the data was not collected at the screening vi sit, the date of collection will be recorded.   
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 18 of 63 3.0 INTRODUCTION 
3.1 Study R ationale  
The ongoing COVID -19 pandemic is an urgent public health crisis with few if any rapid and practical 
solutions.  The outbreak of COVID -19 has been declared to be a public health emergency of international 
concern by the World Health Organization (WHO), and the development of effective therapies for fast -
spreading fatal COVID -19 is in an urgent need  [1]. Given the seriousness and time -sensitive nature of this 
highly contagious virus, the medical and scientific communities must work quickly and effi ciently to find 
a feasible way to address this global emergency.   
COVID -19 begins as pure viral infection, involving viral replication and virulence.  Once progres sed, it 
evolves into a multifactorial disease with components of viral infection, hyper immun e activation, and 
end organ damage and fibrosis. In fact, many of those with progressed COVID -19 do not shed  virus 
anymore and their course can be improved by reducing their immune responses using dexamethasone. 
Thus, the suppression of viral replication, i.e. antiviral effect, is expec ted to be most impactful early during 
COVID -19, when no or mild symptoms are present.   
Unlike remdesivir, which is available only as IV and is therefore mostly limited to patients with severe 
COVID -19 that require hospitalization, favipiravir is available in a tablet  form and can be used  also in 
outpatients with asymptomatic or mild infection  [2].  Progression from mild to severe COVID -19 is more 
frequent among older persons and those with certain underlying comorbidities.  [3]. As a result, such 
populations contribute unproportionally to death  from COVID -19 [4]. The ability to mitigate  COVID -19 
symptoms has the potential to decrease progression to severe COVID -19 and is of great importance as it 
has the potential to save many lives. In addition, early effective treatment is expe cted to shorten and reduce 
viral shed ding [5].  Viral shedding in patients with symptomatic COVID -19 typically continues for 4-15 
days, and sometimes > 15 days. During  this period, patients are considered to be  infectious. Shortening the 
duration of viral shedding may decrease the risk of progression to severe COVID -19 and diminish the 
period of infectivity, thus possibly decreasing the number of secondary cases. Two small  studies from 
China demonstrated that favipiravir decreases the period of viral shedding in symptoma tic patients with 
COVID -19 [6-7]. 
 
3.2 Favipiravir : The study drug   
At the time of writing, definitive therapies for established COVID -19 remain to be defined. Significant 
interest exists in repurposing existing antiviral agents for use against COVID -19.  Favipiravir is a purine 
nucleoside analogue, which acts as a competitive inhibitor of RNA -dependent RNA polymerase  [8-10]. I t 
has activity against influenza A and B including activity against oseltamivir and z anamivir -resistant 
influenza viruses, several agents of viral hemorrhagic fever, a nd SARS -CoV -2 in vitro  [11-13].  
Favipiravir is approved for novel epidemic influenza strains unresponsive to standar d antiviral therapies 
in Japan  [14]. 
Favipiravir was identified to have activity in vitro against SARS -CoV -2, albeit a high concentration w as 
required as compared to chloroquine or remdesivir (EC50 = 61.88 μM)  [15].  D espite a similarly elevated 
EC50 identified for favipiravir and Ebola virus, it was identified in 14 previous a nimal models to be highly 
effective as post -exposure prophylaxis for mice exposed to an Ebola virus challenges, with rapid virologic 
response preventing mortality  [16- 18}.  Based on the dosing strategies and pharmacokinetic data from 
human influenza trials, a n intensified dosing strategy of 6000 mg loading on day 1 followed by 1200 mg 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 19 of 63 PO BID maintenance therapy for 10 days was employed in a single -arm clinical trial for Ebola virus 
disease in Guinea  [19]. 
In a retrospective analysis of 124 patients with Ebola v irus disease in Sierra Leone, those treated with 
favipiravir had a significantly higher survival rate compared to patients receiving suppor tive management 
(56% v. 35.3%, p=0.027)  [20].  Patients received favipiravir 800 mg PO BID on day 1 and 600 mg PO 
BID for days 3 -11. Viral loads were quantified for 35 patients twice during their hospitalizat ion and were 
significantly reduced amongst patients receiving favipiravir.  
Favipiravir has also been used as pharmacologic post -exposure prophylaxis for Ebola virus disease  [21].  
In a case series of four healthcare workers with higher risk Ebola virus exposures, i ncluding two hollow -
bore needle stick injuries, none of the patients who received 10 days of high -dose favipiravir developed 
Ebola virus disease.  
Early clin ical experience with favipiravir for COVID -19 is promising. An open -label nonrandomized trial 
of 80 patients with COVID -19 in China identified a significant reduction in the time to SARS -CoV -2 viral 
clearance in patients treated with favipiravir compared t o historical controls treated with 
lopinavir/ritonavir [6].  Patients with mild or moderate COVID -19 were enrolled within 7 days from 
disease onset; those with severe or critical disease, ≥ 75 years ol d, chronic liver disease, or end -stage renal 
disease we re excluded. Patients in the intervention arm received Favipiravir 1600 mg PO BID on da y 1 
followed by 600 mg PO BID on days 2 -14. Both arms were co -treated with inhaled IFN - α1b 60 μg BID 
and therapy was continued until viral clearance, up to a maximum of  14 days. Thirty -five patients were 
assigned to favipiravir and 45 patients to lopinavir/ritonavir, with a median age of 47 ( IQR 35.8 -61); 
13.7% were ≥ 65 years old. There was a significant reduc tion in the median time to viral clearance with 
favipiravir (4 days; IQR 2.5 -9) as compared to lopinavir/ritonavir (11 days; IQR 8 -13; p <0.001). Further, 
by day 14, 91.4% of patients in the favipiravir arm had radiographic improvement versus 62.2% of the 
lopinavir/ritonavir arm. There was a significantly lower rate  of adverse events in patients receiving 
favipiravir (11.4% v. 55.6%, p<0.01).  
In an open -label randomized trial in China, 240 patients with confirmed COVID -19 were randomized to 
favipiravir or arbidol  [7].  Favipiravir was given at 1600 mg PO twice on day  1 followed by 600 mg PO 
BID until day 7 -10. The clinical recovery rate by day 7 of treatment was higher amongst patients re ceiving 
favipiravir, albeit not achieving statistical significance (61.21% v. 51.67%, p= 0.1396). Amongst patients 
with moderately se vere disease, there was a significantly higher rate of clinical recovery by day 7 wi th 
favipiravir (71.43% v. 55.86%).  
Top- line results are also available from an open- label , randomized, multicenter clinical trial  recently 
conducted in 150 patients in India.  Patient s in the intervention arm  received 1800 mg of Favipiravir PO 
twice daily on day 1 followed by 800 mg twice daily for up to a maximum of 14 days, along with standard 
supportive care. Randomization was stratified based on disease severity into mild ( 90 patients) and 
moderate (60 patients).  The median time to cessation of oral viral shedding was  28.6% faster in the 
intervention arm although  the difference was not statistically significant  (Hazard Ratio 1.367 [95%CI 
0.944,1.979]; p=0.129).   Patients receiving favipiravir were reported to achieve clinical cure faster th an 
controls and disease progression was delayed . No serious adverse events or deaths were reported in the 
intervention arm.   Full study r esult s have not yet been published.  
In the current pandemic crisis, medical professionals are understandably focused m ore on stabilizing the 
very sick. However, if Favipiravir could work in any way to halt or prevent infection in the l ess sick  (or 
even in the uninfected), it would be monumental in terms of returning to normal life .  Because the drug 
has few side effects, taking Favipiravir prophylactically might help to prevent C OVID -19 spreading.  Even 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 20 of 63 if this treatment does not completely era dicate infection, Favipiravir treatment may help to decrease viral 
load, thereby allowing the host immune system to better combat the disease.    
 
3.3 Favipiravir: Risk/Benefit Assessment  
As of August 2020, more than 40 clinical studies with favipiravir have been conducted globally, mainly 
in the US and Japan. Favipiravir has been well tolerated in studies in adults and elderl y subjects with 
uncomplicated influenza  [22] . A consistent safety profile composed of relatively low frequencies of mil d 
to moderate adverse events clustering around the system organ classes of gastroi ntestinal disorders has 
been characterized. Mild to moderate transient, asymptomatic elevations in seru m uric acid and mild to 
moderate diarrhea are the two most common adverse events known to occur with favipiravi r [2].  
Favipiravir has been safely studied with therapy durations up to 22 days (JP120, Phase 1 st udy).  
Favipiravir is considered a safe drug. No related serious adverse events occurred  in licensure studies of 
favip iravir  [23].  Preclinical and animal studies show no direct suppression of white blood cell types  or 
immunosuppression by favipiravir. Genotoxicity studies indicate that favipiravir does not pos e a clinical 
genotoxic risk; however, based on the results of embryo- fetal toxicity studies, favipiravir is not 
recommended for use in pregnant females, those who may become pregnant, or those who are nursi ng. 
Though an inhibitor of CYP 2C8 and aldehyde oxidase, few drugs are contra -indicated. Overall, the safety 
of favipiravir suggests that the potential benefit to human subject s exposed to a confirmed case of COVID -
19 generally outweighs potential risks.  
 
4.0 OBJECTIVES AND ENDPOINTS  
The primary effectiveness objective of this study is demonstrating that treatment with favipiravir for 
COVID -19 patients with mild to moderate symptoms will shorten the time to sustained clinical recov ery 
from study day 1 onward (‘clinical endpoint component’)  compared to placebo . 
The primary virologic objective (the secondary objective of the study)  of the viral shedding sub -study is 
to demonstrate that treatment with favipiravir treatment will shorten the period of  viral shedding (‘viral 
shedding component’)  compared to placebo  from study day 1 onward. 
Demonstrate that treatment with favipiravir will reduce the proportion of sub jects with COVID -19 related 
hospitalizations or emergency department  visits compared to placebo  from study day 1 onward. 
Demonstrate that treatment with favipiravir will reduce th e proportion of subjects with COVID -19 related 
hospitalizations or emergency department visits or the development from study day 1 onward of two or 
more new COVID -19 related symptoms compared to placebo  from study day 1 onward. 
Primary Efficacy Endpoint:  
Time to Sustained C linical Recovery  defined as number of days from start of study treatment to Sustained 
Alleviation of Symptoms . The endpoint will be considered to have been met at the earliest time point from 
study day 1 onward at which the su bject has reached Sustained Alleviation of Symptoms as defined by :  
(1) Blood oxygen saturation >94% on room air at rest  
(2) O ral temperature <38.0  ºC AND  
(3) All COVID -19 associated symptoms (stuffy or runny nose, feeling hot or feverish , chills  or shivering , 
cough, sore throat, lack of energy or tiredness , nausea, headache, muscle or body aches, shortness of 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 21 of 63 breath , vomiting, diarrhea ) (Symptoms related to smell or taste are not included in the primary endpoint) 
reported by the patient have reached a severity of “0 – none ” or “1 – mild” in assessments  for 4 -point scale 
assessments  
To mee t the primary endpoint, criteria 1 through 3 (above) should be met and the subject is not known to 
have redeveloped any COVID -19 associated signs and symptoms (not including reduced sense of taste or 
smell) at a severity beyond mild  for 4 consecutive days  (inclusive of the day when clinical recovery was 
achieved) assessed from the start of study treatment to day 2 8, and subjects must survive with no 
hospitalization to day 28.   The time from start of study treatment to the earliest time  point that one through 
three (above)  are met will be considered for the primary efficacy endpoint.  For example, if clinical 
recovery was reached on study day 5 and sustained over study days 6, 7, and 8, the time of reaching the 
endpoint will be study day 5.  
The subject will  assess and score  the severity of each COVID -19 associated symptom on a 4 -point scale 
(for all symptoms besides vomiting and diarrhea: 0= none, 1= mild, 2=moderate, 3=severe . For vomiting 
and diarrhea: 0 = not at all, 1 = 1 -2 times, 2 = 3 -4 times, 3 = 5 or more times). The patient’s blood oxygen 
saturation and severity of COVID -19 associated symptoms will be evaluated and reported once daily , 
preferably at or around the same clock time , by the subject (for a period of 10 days or  longer in case  that 
the subject does not achieve the primary endpoint within the first 10 days ).  
Beyond Study Day 10, once the subject meets the primary efficacy endpoint, the subject is not  required to 
continue the self -assessment and reporting of COVID -19 symptoms. However, the study team, duri ng all 
the in-person and remote patient  visits will evaluate and report  the severity of each of the COVID -19 
associated symptoms and vitals as per the set frequency mentioned in the Schedule of Activities , under 
study staff responsib ility.  
Subjects who develop new COVID -19 symptoms post -randomization will be counted towards the primary 
outcome. The definition of the primary endpoint for such subjects will be identical to  the definition used 
for any other subjects. To have the endpoint , all symptoms (those existing at enrollment and those 
appearing post -enrollment , not including symptoms related to smell or taste ) will have to be no worse than 
1 - mild, regardless of whether they existed at randomization or not.  
For any subject who has incompl etely submitted relevant data to assess clinical recovery, the primary 
endpoint is met on the first day from study day 1 onward where clinical recovery is reached, defined as 
none of the symptoms is worse than mild , as well as temperature <38.0C and O2 saturation >94%, and 
considered sustained  over the 3 following days when there is no known flare up of symptoms beyond 
mild. During the 3 -day sustainability period, complete COVID symptom dat a (not including taste, sm ell) 
is required for at least 2 of the 3 days  (COVID -19 symptom  data can be missing for 1 of the first two 
sustainability days but not for the last day of sustainability) . Missing information for temperature or O2 
saturation during the 3 -day sustainability period will not invalidate reaching the endpoint.  
For any subject who has been lost to follow -up prior to Day 28, the investigators will make reasonable 
effort s to deter mine whether the subject has been admitted to the hospital or died up to Day 28. For subj ects 
who experienced sustained clinical recovery prior to Day 28 and lost to follow -up, should the investigator 
be able to confirm no admission to the hospital and no death, the subject will be flagged as having the  
endpoint of sustained clinical recovery.  Subjects who were lost to follow -up and for whom the 
investigator could not confirm lack of admission to the hospital or death before Day 28, wil l be flagged 
as the worst possible outcome regardless of clinical recovery.   
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 22 of 63  
 
 
Secondary Endpoints : 
Key Secondary Efficacy Endpoint :   
• Proportion of subjects with COVID -19 progression, where progression is defined as  the occurrence 
from study day 1 onward of any emergency department (ED) visit for COVID -19 worsening or 
shortness of breath OR hospitalization for COVID -19 worsening or short ness of breath OR death  
(narrow progression)  
• Proportion of subjects with COVID -19 progression, defined as the occurrence from study day 1 
onward of any ED visit for COVID worsening or shortness of breath OR hospitalization for  
COVID worsening or shortness of breath OR death OR the development of symptomatic 
worsening from study day 1 onward (defined as >2 additional COVID symptoms at a level  of 
moderate or severe which have not existed at baseline  or fever (temperature of ≥38.0ºC ) which has 
not existed at baseline  or oxygen desaturation (O2 saturation <94%) which has not existed at 
baseline ) (broad progression).  
Viral Shedding Sub -Study: 
• Time (number of days) to negative conversion (defined as undetectable viral load ) of detectable 
SARS -CoV -2 viral RNA in RT -PCR assays of saliva, from start of study treatment to date of last 
viral assessment . Included: all subjects with a positive PCR on study day 1  or 2 or 3 . The endpoint 
will be evaluated from study day 1 onward.  
Additional Secondary Efficacy Endpoints  
• Time (number of days) to negative conversion of positive SARS -CoV -2 viral culture assays of 
saliva, from start of study treatment to date of last viral assessment . Subjects with a positive saliva 
SARS -CoV -2 PCR on any s tudy day will have viral cultures performed. Subjects with a positive 
viral culture on study day 1 or 2 or 3 will be included in this analysis.  The endpoint will be 
evaluated from study day 1 onward.  
 
Exploratory Endpoints  (details of the planned analyses are  described in SAP 3.1) : 
• Proportion of subjects showing sustained clinical recovery by study Day 1, 3, 5, 7, 10, 14, 21.  
• Proportion of subjects showing resolution of Symptoms by Days 1, 3, 5, 7, 10 , 14, 21, where 
resolution is defined as symptom severity of 0 for all symptoms as well as temperat ure of <38.0 
ºC as well as oxygen saturation of ≥94%.  
• Proportion of patients showing negative conversion of detectable SARS -CoV -2 viral RNA in 
saliva on study day 1 or 2 or 3 to undetectable viral load  on Study Days 3, 5, 7,  and 10. Included: 
all subjects with a positive PCR on study day 1  or 2 or 3 . 
• Proportion of patients showing negative conversion of positive SARS -CoV -2 viral culture in saliva 
on Study Days  3, 5, 7  and 10. Subjects with a positive saliva SARS -CoV -2 PCR on any study day  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 23 of 63 will have viral cultures performed. Subjects with a positive viral culture on day  1 or 2 or 3 will be 
included in this analysis.  
• Proportion of subjects dying from any cause over an assessment period from start of study 
treatment until Day 28.  
• Proportion of subject with COVID -19 progression, where progression is defined as  the occurrence 
at any point from study day 1 to study day 28 of emergency department (ED) visit for any rea son 
OR hospitalization for any reason.  
• Proportion of subjects requiring mechanical ventilation over an assessment period fr om start of 
study treatment until Day 28.  
• Time (number of days) to negative conversion (defined as viral load <100 copies) of detecta ble 
SARS -CoV -2 viral RNA (defined as viral load >100 copies) in RT -PCR assays of saliva, from 
start of study treatment to date of last viral assessment . Included: all subjects with a positive PCR 
on study day 1 or 2 or 3. The endpoint will be assessed from  study day 3 onward.  
• Time to Sustained Clinical Recovery defined as number of days from start of study treat ment to 
Sustained Alleviation of Symptoms, evaluated from study day 3 onward.  
• Proportion of subjects with COVID -19 progression, where progression is  defined as the occurrence 
from study day 3 onward of any emergency department (ED) visit for COVID -19 worsening or 
shortness of breath OR hospitalization for COVID -19 worsening or shortness of breath OR death 
(narrow progression)  
• Proportion of subjects with COVID -19 progression, defined as the occurrence from study day 3 
onward of any ED visit for COVID worsening or shortness of breath OR hospitalization for  
COVID worsening or shortness of breath OR death OR the development of symptomatic 
worsen ing from study day 3 onward (defined as >2 additional COVID symptoms at a level of 
moderate or severe which have not existed (at any level of severity) at baseline or fever  
(temperature of ≥38.0ºC) which has not existed at baseline or oxygen desaturation ( O2 saturation 
<94%) which has not existed at baseline) (Broad progression).  
 
Safety Endpoint :  
1. Number (and proportion) of patients reporting treatment emergent adverse events (T EAEs) (by 
MedDRA system organ class and preferred term) . See additional informa tion on assessing adverse 
events under section 9.4.   
2. Number (and proportion) of patients reporting serious treatment emergent adverse event s (TEAEs) 
(by MedDRA system organ class and preferred term).  
3. Vital Signs including oral temperature, heart rate, oxygen s aturation with height and weight.  
4. Clinical laboratory tests including Biomarkers, Chemistry, Coagulation and He matology.  
 
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 24 of 63 5.0 STUDY DESIGN  
5.1 Overall Design 
This is a double-blinded, randomized , placebo -controlled , superiority trial of approximately 1250 adult 
outpatients with mild to moderate symptoms of COVID -19 not requiring hospitalization. Depending on 
the site of enrollment, subject s will be identified at COVID -19 testing centers , testing laboratories , or 
other clinical care s ettings . As this study will enroll outpatients only, to prevent violating quarantine 
requirements and decrease risk of COVID -19 for study team members, most study interactions will be 
performed remotely with  no need for study subjects to leave their homes to fulfill their study obligations . 
Besides study visits on Day 1 and Day 10, which will be in -person , all other study interactions will be 
done remotely , using telehealth and video conferencing. Study materials will be provid ed to subjects at 
their home  or in-site. 
Subject s in the treatment arm (n= 625) will receive favipiravir orally taken approximately every 12 hours  
in addition to current standard of care treatment . The first two doses of favipiravir will be  1800 milligrams . 
The fo llowing doses will be  800 milligrams  for a total of 10 days of therapy .  Those in the control group 
(n= 625 ) will receive placebo  orally, using  the same numbers of tablet s on day 1 and the subsequent  9 
more days (total 10 days of treatment) , in addition to current standard of care treatment.  Saliva PCR 
testing will be performed at an accredited central laboratory . The s ite’s Princip al Investigators will be 
responsible for study  recruitment and engaged as deemed necessary by the Study Team to ensure 
identification and reporting of maximum number of positive cases and prompt subject  engagement/ 
enrollment. This study will be listed at www.clinicaltrials.gov .   
Subject s who provide informed consent , meet all inclusion and no exclusion criteria will be randomized 
on Treatment Day 1 in a 1:1 ratio to either the Treatment Group or the Control Group, in accordance wit h 
a computer -generated schedule prepared by a biostatistician.  The randomization schedule will be 
incorporated into the Interactive Web Randomization System (IWRS) .  Rando mization will then be 
performed by study personnel directly in the IWRS system. Study personnel will be instructed not to 
randomize until subject  has been confirmed to meet all inclusion/exclusion criteria on treatment Day 1.  
 
5.2 Scientific Rationale for Study Design 
Randomized , double blind , placebo control (RDBPC) studies provide the strongest possible evidence of 
causation.  Phase II I trials are used to expand on Phase II research of the efficacy and safety of an 
intervention in subject s with the disease for which a new intervention is proposed.  Randomization in 
combination with blinding helps to avoid possible bias in the selection of subject s, their assignment to an 
intervention or control, and the analysis of their response to the intervention.   
 
5.3 Dose Justification and Tablet s needed  
5.3.1 Justification for Dose  
Favipiravir will be taken approximately every 12 hours. The dosage for favipiravir to be used in this study 
is 1800 mg ( 9 tablet s of 200  mg) orally for the first 2 doses, then 800 mg orally approximately every 12 
hours to complete days 2-10 of therapy. Favipiravir is provided as 200 mg tablets and dosed orally. 
Favipiravir is rapidly and completely absorbed after oral administration of the 2 00 mg immediate release 
tablets. Although discouraged, i f necessary, favipiravir may be crushed for administratio n and can be 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 25 of 63 taken with or without food  [24-25 ].  This dosing strategy is increased from the licensed dosing regimen 
for influenza, to account for the higher in -vitro concentrations required for activity against SARS -CoV -2. 
Elevated dosing strategies, up to 6000 mg on day 1 followed by 1200 mg BID has been used in published 
Favipiravir studies for Ebola  [26].  Prolonged administration to 22 days has been explored in a phase 1 
study in Japan (JP120) with a favorable safety profile (patients received 1800 mg P O BID on day 1 
followed by 800 mg PO BID from day 2 -21 and a single dose of 800 mg on day 22).  
 
5.3.2 Number of tablet s required for the entire study  
For a 10-day course: 1800 mg ( 9 tablet s of 200 mg) x2 doses (a total of 18 tablet s), then 800 mg ( 4 tablet s) 
x2 daily doses until study day 10  (8 tablet s per day to complete 10 days of therapy)  for a total of 90 tablet s 
per subject for the entire study period. Tablet s required for dosing of the entire study population  per 
treatment arm will be  56,250 (625 subjects x 90 tablet s per subject).  
Considering competitive enrol lment involving multiple countries and sites, it is very critical to maintain 
sufficient quantity of IPs at each IP depot and participating sites. Hence, it woul d require to add -on 
approximately 5 0% contingency quantity.  This will make up to total approx imately  85,000 tablets for the 
entire study  per each treatment arm .  
 
5.4 Dosing in Special Populations  
Favipiravir is contraindicated in nursing mothers and pregnant women or women of child -bearing age 
who are not taking oral contraception due to its potential teratogenicity. No alte ration of dosing is needed 
in subjects with renal impairment. Total exposur e for plasma favipiravir for subjects with severe renal 
impairment (Stage 4) was 1.3 -fold higher compared to subjects with normal renal function. No obvious 
effect of renal impairment on safety was observed and favipiravir treatment was g enerally well tole rated 
in subjects with renal impairment.  
No alterations in dosing strategies are required in older adults. The maximum pla sma concentration and 
AUC values in elderly subjects in a single and a multiple -dose study completed in Japan were higher than 
in young subjects. Comparing AUC values on Day 5, the differences were 40 and 80% after 600 mg once 
a day and 400 mg BID, respectively. In the companion study completed in the United States of Ame rica, 
there were no differences between young and older populations  based on Day 5 AUC comparison in 
subjects receiving either 600 or 800 mg BID.  
 
5.5 Storage and Stability  
Favipiravir is a novel nucleic acid (pyrazine molecule) analogue that interfer es with viral ribonucleic acid 
(RNA) replication. Favipiravir is supplied as a light yellow, film -coated tablet for oral administration 
containing 200 mg favipiravir. Favipiravir tablets are to be kept in a dry area, store d at 15° C to 30° C and 
shielded from direct light.  
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 26 of 63 5.6 Study Drug Dispensation  
Study drug will be provided from IP depot  to the research site.  The research site study team member  will 
distribute the IP to each enrolled subject. If transportation is needed, t he research site study team member  
will be responsible for transporting of medications to each enrolled subject.  
 
5.7 Expected Side Effects  
Favipiravir is considered a safe drug. No treatment related serious adverse event s occurred in licensure 
studies of favipiravir  [2].  The most common adverse events observed in clinical trials are gastrointestinal 
(diarrhea 2.3%; nausea 2.1%). A similar proportion of subjects in the placebo (25.4%)  and favipiravir 
(25.3%) groups experienced at least 1 adverse event. Further , favipiravir is associated with increased uric 
acid level which are typically asymptomatic and would be expected to be transie nt with the duration of 
treatment to be used in this trial.  
 
5.8 Additional Safety Considerations  
For the purpose of  this trial, the following are exclusion criteria for study drug administration:  
1) Subject has a history of hypersensitivity to favipiravir  
2) Known uncompensated hepatic cirrhosis.   
3) Current use of the following medications, which cannot be discontinued for the duration of t he 
study: pyrazinamide, hydralazine, more than 3000 mg of acetaminophen per day.  
 
The following safety considerations are based on data from individuals taking fav ipiravir for influenza. 
They are listed here for reference.  
• Phototoxicity: Nonclinical studies have shown mild phototoxicity. One study subject experie nced 
mild photosensitivity (rash) following a tanning bed session. All subjects should avoid exces sive 
exposure to sunlight or artificial ultraviolet light.  
• Laboratory Values: Mild to moderate asymptomatic elevations of uric acid and aminotr ansferase 
have been observed in healthy volunteers and subjects with influenza  [2] treated with favipiravir 
in clinical studies. The changes have been reversible upon favipiravir discontinuation.  
• Mutagenesis: Favipiravir proved mildly positive under some conditions studied in the mamm alian 
chromosomal aberration test and mouse lymphoma assays at high concentrations. Althoug h the 
potential for genotoxicity at high exposures cannot be ruled out, evidence indicates that this risk 
is minimal at the exposures planned in this clinical study.  
• GI Tract Lesions: In two proof -of-concept studies of orally administered favipiravir against Ebola 
virus infection in macaques, GI tract lesions were observed that were not consis tent with the known 
natural history of Ebola nor with previous animal and clinical studies of favipiravir. H owever, 
evidence suggests that bacterial infections and pre -existing enterocolitis in the treated macaques 
may have been responsible, and an ongoing risk to subject s may not exist.  
• Contraception: 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 27 of 63 Females of Childbearing Potential   
Female subjects  who are of childbearing potential  must use an acceptable method of contraception 
starting from screening through to at least 7 days following the last dose of study me dication .  
Acceptable contraceptive methods for female subjects of childbearing potential inc lude one of the 
following:  
1. Abstinence.  
2. One of the following methods:  
− Tubal ligation  4 or more weeks prior to randomization  
− Copper- containing intrauterine device (IUD).  
− Condom AND spermicidal foam/gel/film/cream/suppository.  
− Male partner who has had a vasectomy for at least 6 month s.  Male partners with 
vasectomies of <6 months are NOT considered protected.  
− Hormonal contraceptives (oral, injected, transdermal or implanted).  The subj ect 
must remain on the treatment throughout the study and must have been using 
hormonal contraceptives for an adequate period to ensure effectiveness (3 months  
prior to randomization or longer ). 
 
Females of Non -Childbearing Potential   
Female subjects of non -childbearing potential must meet at least one of the following criteria:  
1. Postmenopausal females  (Not menstruating for at least one year ) 
2. Females who have a documented hysterectomy and/or bilateral oophorectomy.  
All other females will be considered to be of childbearing potential.  
Men 
Men must meet at least one of the following criteria:  
1. Known to be sterile (have azoospermia)  
2. Underwent va sectomy  
3. Use condom   
 
5.9 E nd of S tudy Definition 
A subject  is considered to have completed the study if he or she has completed all phases of the study 
including the last visit or the last scheduled procedure shown in the section of Schedule of Activities , or is 
hospitalized or dies before the 28 day follow -up visit . 
5.9.1 Early Termination/Hospitalization  
All subject s have the right to withdraw  from study participation at any time during the study. If, for 
whatever reason, a subject  withdraws from the study  or is hospitalized for increased severity of COVID -
19 symptoms or other cause , an Early Termination Visit will be performed  as deemed feasibl e by the PI 
or qualified designee .   
 
Any AE , SAE  or other medical condition or situation that occurs such that continued participation in the 
study would not be in the best interest of the subject will result in early termination.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 28 of 63  
The following procedures will be performed at  the Early Termination  Visit: 
1. Assess for AEs 
2. Document all current medications, including medications over the counter  and herbal 
medications  
3. Perform clinical assessment (as deemed feasible if hospitalized)  
4. Evaluate for increased severity of COVID -19 related disease and symptoms   
5. Pregnancy Test for women of child -bearing potential  
 
If clinical evaluation is deemed not  feasible due to subject’s condition, the study t eam will collect  as much 
of the Early Termination Visit data and attempt to complete Day 21 and Day 28 assessments and AE 
assessment for those who are hospitalized and deemed off study . 
 
6.0 STUDY POPULATIO N 
6.1 Inclusion Criteria  
The study will include subjects with mild -to-moderate COVID -19.33 Study subjects should meet all of  the 
following criteria:  
 
1. Adults age 18 or older  
2. Tested positive for SARS -CoV -2 by RT -PCR or Rapid Antigen assay ( first positive test) using a 
respiratory tract sample (either nasopharyngeal swab OR oropharyngeal swab OR nasa l aspirate 
OR tracheobronchial aspirate OR saliva) collected within 72 hours  of randomization  
3. Stated willingness to give their written informed consent to participate in the study  
4. Stated willingness to comply with all study procedures and availability for the duration of  the study  
5. Males must be sterile, OR agree not to donate semen AND agree to strictly adhere to con traceptive 
measures (e.g. condom use) during the study and for 7 days following the last dose of study 
medication  
6. Females must be unable to bear children, OR ensure that their male partner is incapab le of fathering 
a child, OR, if of childbearing potential will strictly adhere to contracepti ve measures during the 
study and for seven days following the last dose of study medication (as detailed in section 5. 8) 
7. Females must agree to stop breast -feeding prior to first dose of study drug and through seven days 
after completing therapy  
8. Females must have a negative pregnancy test at screening  
9. Ability to take oral medication and be willing to adhere to the favipiravir/placebo  regimen  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 29 of 63 10. Minimal baseline severity score for COVID -19-related symptoms: at least two symptoms with a 
score of 2 or higher . COVI D-19- related symptoms include: Stuffy or runny nose, sore throat, 
shortness of breath, cough, lack of  energy or tiredness, muscle or body aches, headache, chills or 
shivering, feeling hot or feverish , nausea, diarrhea, vomiting . (Excluding changes in the sense of 
taste or smell ).  
11. Subject has access to a smart phone , tablet, or PC  
6.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation i n this study:  
1. O2 saturation <94%  
2. Shortness of breath at res t  
3. Heart rate ≥ 125 per minute  
4. COVID -19 symptoms first presented >5 days prior to randomization  
5. Requirement for hospitalization at the time of enrollment  
6. Participation in another trial or use of any experimental treatment for COVID -19 
7. Treatment with high steroid dose i.e. >30 mg/day prednisolone equivalent (excluding stable 
chronic treatment) or remdesivir  or anyone receiving SARS -CoV -2 monoclonal antibodies within 
3 months prior to enrollment  
8. Known sepsis or organ dysfunction/ failure  
9. Known infection with a respiratory virus other than SARS -CoV2 (e.g. Influenza) or any known 
bacterial infection (affecting the respiratory system or any other system)  
10. Inability to adhere to study requirements  
11. For premenopausal women: unwilling or unable to use effective birth control measures  
12. Known allergy to favipiravir  
13. Known end -stage kidney disease or requiring hemodialysis or continuous ambulatory peritoneal 
dialysis (CAPD)  
14. Known liver impairment greater than Child -Pugh A  
15. Psychiat ric illness that is not well controlled (defined as stable on a regimen for mor e than one 
year).  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 30 of 63 16. Known elevated uric acid levels in the past year or taking uric acid lowering medicati ons 
(allopurinol, febuxostat)  
17. History of hereditary xanthinuria or history of xanthine urolithiasis.  
18. History of gout or actively being treated for gout.   
19. Current use of the following medications, which cannot be discontinued for the duration of t he 
study: pyrazinamide, hydralazine, more than 3000 mg of acetaminophen per day.  
6.3 Lifestyle Considerations  
No special preparations or additional steps (for example, special diets, fasti ng, other medicines, laxatives, 
or enemas) are necessary before, duri ng, or immediately after taking favipiravir.   For reasons unrelated to 
study participation, the standard of infection prevention in communities is the quara ntine of individuals 
who test positive for COVID -19. T his standard is expected to continue and be practiced  throughout the 
study period in all countries and states where the study will be enrolling.  
 
6.4 Screen Failures  
Screen failures are defined as subject s who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of screen 
failure information is required to ensure transparent reporting of screen fai lure subject s, to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and t o respond to 
queries from regulatory authorities. Minimal information includes demography, s creen failure details, 
eligibility criteria, and any SAE.  
 
6.5 Strategies for Recruitment and Retention  
The strategy for recruitment will depend on the site of recruitment. Subjects will be identified at COVID -
19 testing centers at the occasion of testing , through COVID -19 testing laboratories upon receipt  of testing 
results , or at other clinical care settin gs. When identified at testing centers, tested individuals will be asked 
for their permission to be approached after testing to inquire about their intere st to participate in the study.  
HIPAA -governed procedures related to subject enrollment into this stu dy will be practiced in a HIPPA -
compliant manner  or Lei Geral de Proteção de Dados Pessoais (LGPD)  in Brazil . This will include:  
1) Obtaining IRB approval to approaching persons who may test or have tested positive for SARS -
CoV2  
2) Testing centers, testing labs, and care organizations that are involved in the study and w hose 
clinical role is to report SARS -CoV2 test results, will read a statement to patients who tested 
positive to get their verbal permission to be called by the study team about the study  
3) The statement will be as followed: “You may test/ have tested positive for COVID -19 and may be 
eligible to participate in an Appil i Therapeutics research study from the comfort of your home.  
We are asking for your permission to provide your contact information to the clinical  research 
team who will contact you to see if you are interested in participating. If you’d like to r each out  to 
the research team yourself, the direct number is XXX -XXX -XXXX"  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 31 of 63 4) Those who provided a verbal permission  to be approached after testing , will be called by the study 
team.  
5) Individuals who express interest to participate in the study will be screened f or inclusion and 
exclusion criteria. If they qualify, they will be educated about the study medications  and the study 
procedures. If they consent to participate, they will be randomized into the study.  
6) If required, social media may be used to enhance recruit ment.  
 
7.0 STUDY INTERVENTIONS 
7.1 Study Intervention(s) Administration 
7.1.1 Study Supplies  
On study day 1, after randomization, study subject will be supplied the study kit.  The study kit will include 
the following:   
1. Thermometer with the specific instructions how to measure and document temperature  
2. Fingertip probe pulse oximeter, with specific instructions how to measure and docum ent oxygen 
saturation  and heart rate . The relatively low reported percentage of error for the finger probe 
supports that the finger probe is the modality of choice to measure intermittent oxyge n saturation 
in the outpatient setting . 
3. Sterile saliva collection tubes  
4. IP kit ( Favipiravir or placebo tablet s).  
5. For premenopausal  (child bearing potential)  women: Urine pregnancy test . To be performed on 
Day 1, Day 7, and Day 28 (or earlier in the case of early study termination).  
6. On randomization  (Study Day 1 ), subjects will be educated and trained on the use of the 
thermometer, pulse oximeter, pregnancy test.   
 
7.1.2 Study Vital Signs Measurements  and Health Information  
• Oral Temperature: will be measured 2 times  daily . It will be documented in the subjects’ diary. 
Subjects will be  allowed to take temperature lowering medications such as acetaminophen or 
NSAIDS.  
• Heart rate: will be measured once daily and documented by the subject in the subject’s diary.  
• Oxygen Saturation: will be measured once daily and documented by the subject in the subject’s  
diary. If the O 2 saturation result is 90 -93%, the subject will repeat the measurement 2 hours later. 
If the result is <90%, the subject is instructed to contact the study team. The study team will decide 
if a recheck in 2 hours is appropriate or the subject needs further medical evaluati on).  
• Height and weight:  Height and weight should be collected at the screening visit.  In cas es where 
this has not occurred  at the screen ing visit, the date of collection will be recorded.   
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 32 of 63 7.1.3 Dosing and Administration  
Subjects will be randomly assigned to favipiravir ( the first two doses are 1800mg given approximately 12 
hours apart and followed by 800mg approximately every 12 hours  to treatment day 10 ) or identically 
dosed placebo  in 200 mg tablet s. All tablet s will be supplied in a bottle .  
 
7.2 Preparation/Handling/Storage/Accountability     
7.2.1 Acquisition and accountability  
In accordance with recent COVID -19 FDA Guidance, if scheduled visits at clinical sites are  significantly 
impacted, certain IP, such as those that are typically distributed for self-administration, may be amenable 
to alternative secure delivery methods , via a courier. 
Favipiravir and matching placebo (Investigational Product, IP) will be stored in central IP depot  and 
research site.  Upon enrollment, the research  site will dispense the IP to the subject . The entire supply of 
study medication will be dispensed at one time . Subjects will be asked to document compliance with study 
protocol in a subject diary. If a subject does not use all the IP, the remainder shall be r eturned  to the study 
site by day 28 . Returned IP and u nused IP that has never been delivered to subjects will be returned to the 
IP depot with prior approval of CRO/ Sponsor . 
The study medication will be packed in individual subject’s kits, labeled with study specific labels, and 
supplied to the study sites.  Labels will reflect appropriate dosing and storage infor mation, the use for the 
investigational purpose only, plus a unique number that will be used to assign the medication  to the subject 
according to their randomized treatment assignment (IWRS).  
 
7.2.2 Formulation, Appearance, Packaging, and Labeling  
Table 1. Formulation, Appearance and Composition of Favipiravir®  
Formulation  C 5H4FN 3O2; favipiravir  
Appearance  Light yellow to yellow, film-coated, round tablets, plain on both sides  
Packaging  HDPE Bottles with induction seal and child resistant cap.    
Sample Label  CFR 21 Part 312 Sec. 312.6 Labeling of an investigational new drug. :  
Protocol#: ATI0220 
Product Name: Favipiravir / Placebo  
Strength/Formulation: 200mg/Tablet  
Quantity per container:  
Lot/batch number:  
Expiration/retest date:  
Medication number (Kit no. ): 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 33 of 63 Storage requirements:  15-30 °C  
Investigator: 
Subject  number: 
Name and address of sponsor: Appili Therapeutics Inc. , 21-1344 
Summer Street, Halifax, Nova  Scotia, B3H 0 A8, Canada  
Emergency Contact:   
Keep away from Children  
Caution: New Drug - -Limited by Federal law to investigational use.  
 
7.2.3 Product Storage and Stability  
Favipiravir and the matching placebo are oral tablets. They can be stored at room temperature,  25°C (77°F) 
with excursions permitted to 15 -30°C (59 -86°F). Short- term excursions to higher temperatures during 
shipping and handling, e.g.  to 40 °C, do not affect the quality of the material as a satisfactory stability was  
also shown under these conditions.   
 
7.2.4 Preparation  
There will be no significant preparation. Tablets will be dispensed in a  white  HDPE Bottle with induction 
seal and c hild resistant cap  in accordance with state and federal regulation . Favipiravir may be crushed 
for administration and can be taken with or without food  [24-25]. 
 
7.3 Measures to Minimize Bias: Randomization  and Blinding  
Subject s who sign informed consent and meet all inclusion and none of exclusion criteria will be 
randomized on Day 1 in a 1:1 ratio to either the Test (Favipiravir) or Placebo , in accordance with a 
computer- generated schedule prepared by a biostatistician.  The ra ndomization schedule will be 
incorporated into the IWR S.  Randomization will then be performed by study personnel directly in the 
IWR S. Study personnel will be instructed not to randomize until subject  has been confirmed to meet all 
eligibility criteria of the study . 
As all members of the study t eam will be blinded, Investigational Drug Services (IDS)  and/ or IP depot  
will be unblin ded and will dispense both the favipiravir  and pl acebo , as needed . The study intervention 
(favipiravir ) and placebo will be packaged as indistinguishable as possible .   
Assignment of Subject Identification (Screening number ), Randomization number and study medication, 
as well as site drug inventory control and emergency subject unblinding, will be manage d by an automated 
Interactive Web system (IWRS). A manual containing complete instructions fo r web access and use will 
be provided to each site prior to study start. During screening, the IWRS will as sign a S creening Number 
(Subject ID number). Each Subject ID number will be unique and serve as the primary subject identifier 
throughout the study. The subject ID number must appear on all CRF pages, source documents and lab 
data. Subjects qualifying to enter the double -blind treatment phase, will be assigned an additional 
Randomization Number by the IWRS at  baseline visit on day 1, before the drug is dispensed.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 34 of 63  
Example of Site ID, Subject ID and Randomization Number *:  
 
* Other numbering pattern can be adopted and defined in separate plan/ manual.  
 
Refer to Section of Statistical Considerations  for sample size calculations.  
 
7.4 Study Intervention Compliance 
During the Baseline and Screening  (Day 1), the Principal Investigator (PI)  or qualified designee will 
review the study with the subject  and obtain informed consent and  follow  Lei Geral de Proteção de Dados 
Pessoais (LGPD)  in Brazil or  Health Insurance Portability and Accountability Act of 1996 (HIPAA) 
authoriza tion, where applicable . A second member  of study t eam (e.g., the study C linical Research 
Coordinator (CRC) ) will serve as a witness to the informed consent. After the informed consent is 
obtained, the subject  will be assigned a unique enrollment number. The subject will then be randomized 
to treatment in IWRS  and provided blinded treatment (either Favipiravir or placebo) and other study 
materials .  
On Treatment Day 1, a member of the study t eam or study CRC  will review the dosing and schedule of 
favipiravir / placebo  with the subject .   
• The subject  will be instructed to record all do ses in Study Drug Administration Diary  
• During each remote patient  visit, the study CRC or other Study Team member will review the 
diary with the subject   
• The subject  will be advised not to discard any study tablet (s)  
 
Refer to the Section of Schedule of Activities.  
 
7.5 Concomitant T herapy  
Concomitant therapies are any new or existing medications or therapy taken by the subject  including:   
Drugs, including but not limited to, prescription, over the counter, birth control tablet s/patches/hormonal 
devices, and homeopathic preparations . 
• Nondru g therapies, including but not limited to, thermal/laser/radiation procedures,  vitamins, 
herbal medicines/supplements.  

 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 35 of 63 During the screening process, information on all concomitant therapies, medications,  and procedures will 
be recorded in the source documents and appropriate Case Report Form (CRF)  along with the diagnosis 
or reason for use. Once the subject  receives the first dose of study drug, recording of concomitant therapies 
will be limited to any new medication or modification of an existing medicatio n taken for treatment of an 
AE. These therapies will be recorded in the source documents and appropriate CRF  along with the 
diagnosis or reason for use. Those therapies used for the treatment of an adverse event ar e to be linked to 
an AE and documentation of the AE must also be completed  
 
7.5.1 Rescue Medicine  
The study site will not  supply rescue  medication . 
 
7.6 Telemedicine  
The sites will use their existing remote patient visit (e.g. telehealth ) platform in accordance with any local, 
state or country regulations.  (E.g. AM Well, Doximity, or other).   
Subjects must have access to a smart  phone , tablet or PC  to participate in the study.  Subjects will be 
guided through the step -by-step setup  on their smart phone by the study CRC.  Guidance will be pr ovided 
to the study CRCs to ensure that instructions provided to subjects are consistent.  For  example, the study 
CRC will provide instruction in simple, easy to understand language such as, “I am going to take a minute 
and walk you through signing up for the app so you are ready on your visit date”. “I’ve have actually 
gone ahead and scheduled the visit for you in the app”. “The app is navy blue, has a picture of a doctor 
with a stethoscope and lighter blue heart”.  Once set up, a reminder of the upcoming appointment will be 
sent to the subject via email , text message , or phone call .   
 
7.7 Viral Shedding Testing  
7.7.1 General Description of the Testing Process  
The specimen to be tested for SARS -CoV2 RNA and viral cultures is saliva. The choice of saliva as the 
specimen stems from the need to minimize risk and discomfort to subjects as they wil l be having the test 
on 10 consecutive days. Both nasopharyngeal and mid -turbinated specimens require a semi -invasive 
collection procedure, whic h is less safe, less feasible, and associated with discomfort. The saliva specim en 
will be collected by the subject at their residences. Education and training on spec imen collection will be 
provided in the clinic by a study team member on Day 1 . The speci men will be transferred to the study’s 
central laboratory in two occasions during the first 10 days of the study (Study Days 5+1 and 10+1 ). An 
approved PCR -based test will be performed by the accredited study’s central laboratory.  Viral cultures 
will be pe rformed for sub jects whose day 1 or 2 or 3 saliva specimen is PCR positive.  
7.7.2 Specimen Collection Kit  
On Study Day 1, the subject will be supplied the study kit. It will include 11 (1 extra) sterile saliva plastic 
collection containers of 10 mL each labeled as ‘Study Day 1’, ‘Study Day 2’ and so on.  
7.7.3 Specimen Collection Days  
Saliva Specimens will be collected by the subject at Study Days 1  to 10 . Care will be taken to ensure that 
sampling methods are consistent for each individual subject  across all included timepoints, to limit any 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 36 of 63 bias due to potential differences in viral load.  The first collection of saliva samples will be observed by a 
Study Team member during Day 1 in -person visit .   
7.7.4 Specimen Collection Procedure  
Saliva collection, storage, and shipment procedure:  
Subjects will be trained by a study team member of the technique of saliva collection.  Saliva collection 
will be observed by the study team member.  
1) Saliva will be collected into an empty sterile mL -marked tube (lacking preservatives or buffers).  
2) The subject will wash hands before opening the test package.  
3) Within 30 minutes of the saliva collection, the subject will avoid eating, drinking, s moking, 
chewing gum, or brushing their teeth.  
4) The subject will spit their saliva into the tube until the saliva reaches the black line on  the tube (2 
ml).  
5) The subject will remove funnel and screw on cap to release blue preservation agent in to the tube.  
6) The subject will place the specimen in the provided biohazard bag. Seal the biohazard ba g by 
closing the zip lock seal. Wipe the bag with the provided alcohol wipe. Wash hands thoroughly 
again.  
7) The subject will keep the tube at room temperature.  
8) Saliva tubes collected on study days 1 -5 (4 x 24 -hour periods are required to complete their 
collection) will be shipped on study day 5  (+1) from the subject’s home to the central laboratory.  
9) Saliva tubes collected on study days 6 -10 will be collected by a study team member on study day 
10 (+1) and shipped to the central laboratory.  
10) Specimens will be processed and tested immediately after their arrival at the central laboratory.  
7.7.5 Specimen storage until shipping to laboratory  
The saliva specimen remains stable for at least 10 days in room temperature. It  will be stored at the 
subject’s residence at the collection container in room temperature.  
7.7.6 Specimen Shipping  
The saliva specimens will be shipped to the testing laboratory in two batches: on St udy Day 5+1 and Study 
Day 10+1. The specimens will be shipped in room temperature.  
7.7.7 Specimen Testing  
The specimens will be tested to identify RNA copies of SARS -CoV2 by means of a semi -quantitative 
RT-PCR technique using FDA approved ‘Saliva  Direct’ testing protocol.34 For quantitation of RNA in 
the specimen - as there is no FDA -approved quantitative RT-PCR for SARS -CoV2, we will be u sing the 
following methodology:  
 
1) The PCR CT counts will be documented for each specimen ,  
2) To estimate RNA viral loads from CT counts, external controls with known RNA load  will be 
used,  
3) The controls will be PCR tested and their CT count will be correlated to their know R NA load ,  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 37 of 63 4) These data will be used to create a validated curve associating CT counts to RNA load,  
5) The curve will be used to estimate RNA loads in specimens from trial subjects.   
 
The sensitivity and specificity of FDA approved ‘Saliva  Direct’ testing protocol when comparing saliva 
to the gold standard specimen of nasopharyngeal swab are 94.1% and 90.9%.34  As for the stability of 
SARS -CoV2 RNA in saliva specimens lacking preservati ve or buffer and kept in room temperature - initial 
studies demonstrated adequate stability for at least 5 days (as an example - the Advanta Dx SARS -CoV -2 
RT-PCR Assay, which has an EUA approval by FDA).35 Additional studies demonstrated adequate 
stability up to 21 days (pre -published data).35 
 
Saliva specimens from subjects tested positive by PCR on any study day  will be processed for SARS -
CoV -2 viral cultures. Culture positivity will be determined by scre ens for SARS -CoV -2 induced 
cytopathic effect of Vero E6 TMPRSS2 cells  after 3 days of incubation. The screen is appropriate for 
nasal or saliva samples from patients that are known to have the SARS -CoV -2 virus infection by PCR.   
 
In addition, testing will be performed to evaluate the possibility of viral resistance  and to identify SARS -
CoV -2 variants (including but not limited to variants B.1.526, B.1.525, B.1.617, P.2, B.1. 1.7, B.1.351, 
P.1, B.1.427, B.1.429 , as well as other dominant variants that emerge during the pandemic ).  The 
identification of f avipiravir variants, as well as favipiravir mutations that could confer favipiravir drug 
resistance will be performed using whole genome sequencing.  Attempts will be made to compare paired 
specimens (i.e., from the same subject) collected before or early during the favipir avir dosing period and 
specimens collected at or near the end of the favipiravir dosing period.  
 
8.0 STUDY INTERVENTION DISCONTINUATION AND SUBJECT WITHDRAWAL/ 
DISCONTINUATION  
8.1 Discontinuation of Study Intervention  
This study may be temporarily suspended or prematurely terminated if there is enough reasonable cause.    
If the study is prematurely terminated or suspended, the study team will promptly inf orm the Study Review 
Board  and will provide the reason(s) for the termination or suspension.  
Discontinuation from study treatment does not mean discontinuation from the study, and remai ning study 
procedures should be completed as indicated by early termination proce dures in Section 8.2.3 of the study 
protocol. The possible reasons for early study discontinuation are listed in Section 8.2.2 and w ithdra wal 
procedure is described in Section 8.2.1.  The subjects will be contacted by the study tea m remotely (for 
example, by using phone or telehealth  application) to complete these procedures.  If a clinically significant 
finding is identified (including, but not limited to changes from baseline) after enr ollment, the investigator 
or qualified designee will determine if any change in subject  management is needed. Any new clinically 
relevant finding will be reported as an AE. During the early termination visit upon withdrawal or 
discontinuation, the subject will be accessed for AEs, the use of any concomitant medications will be 
documented, a clinical assessment will be performed (if feasible  and p ermitted), an assessment of COVID -
19 symptoms will be conducted, a test for pregnancy in women of child -bearing potential will be 
completed, and any used -IP will be returned by the subject. All information will be documented in the 
CRF.  If a study participant withdraws or is discontinued from the study, they will not be re placed.  
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 38 of 63 8.2 Subject  Discontinuation/Withdrawal from the Study  
8.2.1 Study withdrawal procedure  
All subject s are free to withdraw from participation  in the study  at any time, for any reason, specified or 
unspecified, and without prejudice.  Reasonable attempts will be made by the Investigat or to provide a 
reason for subject  withdrawals. The reason for the subject ’s withdrawal from the study will be specified 
in the subject ’s source documents and the CRF. The study team will make every effort to contact subject s 
who are lost to follow -up.  Attempts to contact such subject s will be documented in the subject ’s records 
(e.g., times and dates of attempted telephone contact, receipt for sending a regi stered letter, etc.).  
8.2.2 Reasons for early study discontinuation  
A subject  may be discontinued from the study at any time if the subject , the study team or PI feels that it 
is not in the subject ’s best intere st to continue.  The following is a list of possible  reasons for study 
discontinuation: 
1) Subject decides to withdraw their consent  
2) Occurrence of any SAE that the site investigator believes is or may be rela ted to the study drug  
3) Occurrence of 2 or more grade 4 or higher AE that the site investigator believes is or ma y be related 
to the study drug [CTCAE v -5 has 5 severity grades/ s ee attached]   
4) Based upon the decision of the site PI: the occurrence of any medical condition or situat ion that is 
creating a situation in which continued study participation will not be in the subject ’s best interest  
5) Any death of a subject that the site investigator believes is or may be related to the s tudy drug  
6) The subject is lost to follow -up 
7) Subject hospitalization for any reason at any point during the 28 days of the study  
8) The subject has become pregnant  
8.2.3 P rocedures to be perform ed at the Early Termination visit  
• Assess for AEs  
• Document all current medications, including medications over the counter and herbal me dications  
• Perform clinical assessment (as deemed feasible if hospitalized)  
• Evaluate for increased severity of COVID -19 related disease and symptoms  
• Pregnan cy test for women of child -bearing potential  
If clinical evaluation is deemed not feasible due to subject  condition, the Study Team will collect as much 
Early Termination Visit  data as possible from  the Electronic Medical Record  
The reason for subject  discontinuation or withdrawal from the study will be recorded on the CRF.   
 
8.3 L ost to Follow-Up 
A subject  will be considered lost to follow -up if he or she fails to complete more than (2) scheduled remote 
patient  visits and is unable to be contacted by the study staff.  
The following actions must be taken if a subject  fails to appear for a required  telemedicine  study visit:  
1. The Study Team  will attempt to contact the subject  and reschedule the missed visit and counsel 
the subject  on the importance of maintaining the assigned visit schedule and ascertain if the subject  
wishes to and/or should continue in the study.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 39 of 63 2. Before a subject  is deemed lost to follow -up, the investigator or designee will make every effort 
to regain contact wi th the subject  (where possible, 3 telephone calls and, if necessary, a certified 
letter to the subject ’s last known mailing address or local equivalent methods). These contact 
attempts will  be documented in the subject ’s medical record or study file.  
3. Shou ld the subject  continue to be unreachable, he or she will be considered to have withdrawn 
from the study with a primary reason o f lost to follow -up. 
For subject s considered lost to follow -up, the CRF will be completed up to the last contact with the subject . 
 
9.0 STUDY ASSESSMENTS AND PROCEDURES  
9.1 Efficacy Assessments  
The specific timing of procedures/evaluations to be done at each study visit are found in Section of 
“Schedule of Activities ”.  All assessment will be performed by the study investigators and/ or a qualified 
member of the study team.   
 
9.2 Study Procedures  
9.2.1 Screening, Baseline, Randomization and Treatment (Day 1)  
The following procedures will be performed at the Day 1 in -person visit:  
• Confirmation of positive SARS -CoV -2 test result  
• Confirm subject meets all inclusion and none of the exclusion criteria  
• Review the study with the subject and obtain written informed consent and Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) authorization, or equivalent in a nother 
respective country,  as applicable  such as  Lei Geral de Proteção de Dados Pessoais (LGPD)  in 
Brazil  
• Register the subject in IWRS to allot a unique subject ID (screening number)  
• Randomize subject to treatment arm in IWRS as per randomization schedule  
• IWRS to assign unique randomization number to the subject  
• IWRS to assign IP kit number as per randomization schedule  
• Record demographics (age, race, ethnicity, gender)  
• Review and record medical history, surgical history  
• Review and record smoking, alcohol and medication  history 
• Document all current medications, including medications over the counter and herbal me dications  
• Record height and weight  
• Record COVID -19 symptoms  for inclusion  
• Record confirmation of positive SARS -CoV -2 test result  
• Record number of days since onset of symptoms  
• Collect blood sample for below listed blood tests:  
o CBC with differential , Electrolytes, BUN, Creatinine, Random Blood Serum Glucose, 
AST, ALT, Bilirubin, uric acid, SARS -CoV2 IgG, IL -6, IL -10, ESR, CRP, D -Dimer, 
ferritin. (CRP =  C-reactive protein, IL -6 = Interleukin -6, IL -10 = Interleukin -10, CBC = 
Complete Blood Count).  
o Site do not require to wait for blood test result to randomize subjects.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 40 of 63 • Provide the allotted IP kit, the blinded treatment (either favipiravir or placebo) , and other study 
materials to the subject   
• Assist the subject in downloading the ePRO app, create ePRO credentials for the s ubject, train the 
subject on how to use the ePRO and enter the Day 1 Dose 1 visit data with the subject during the 
visit to ensure the subject ’s understanding.  
• Until the sub -study enrollment is completed (112 events have been counted), all subjects will be 
enrolled into the viral shedding sub -study. Howe ver, if they choose so, subjects can opt -out of 
participating in the viral shedding sub -study.  
9.2.2 Treatment Day 1 to Day 10 
• In-person clinical assessment will occur on study Day 1 as described in section 9.2.1 and on Day 
10 as described in section 9.2.3.  Remote patient visits will occur on study Day 3,  5, 7, and 9.  
• Subjects to self -administer IP ( Favipiravir / Placebo) as per the instruction provided and report in 
diary twice daily. Site staff to assess IP adherence daily . 
• Subjects to report Adverse Event and Concomitant Medications including OTC and herbal  
products daily.  
• Site staff to assess Adverse Event  and Concomitant Medications including OTC and herbal 
products daily  
• Subject to c ollect oral temperature twice  daily , and report in the diary .  
• Subject to  collect oximetry data once daily, with the caveat that if O 2 goes below 94%, an 
addition al oximeter reading should be taken 2 hours later.  If the daily O 2 saturation result is 90 -
93%, the subject will repeat the measurement 2 hours later. If the result is <90%,  the subject is 
instructed to contact  the study team. The study team will decide if a recheck in 2 hours is 
appropriate or the subject needs further medical evaluation)  
• The patient’s severity of COVID -19 associated symptoms will be evaluated and reported once daily, 
preferably at or around the same clock time, by the subject (for a period of 10 days or longer in c ase 
that the subject does not achieve the primary endpoint within the first 10 days). The st udy team will 
be reviewing the data reported by subject to ensure compliance, accuracy and completene ss on days 
1, 3, 5, 7, 9, 10, 14, 17,  21, 24, and 28.  
• The subject will assess and score the severity of each COVID -19 associated symptom on a 4 -point  
scale (for all symptoms besides vomiting and diarrhea: 0= none, 1= mild, 2=moderate, 3= severe. 
For vomiting and diarrhea: 0 = not at all, 1 = 1 -2 times, 2 = 3 -4 times, 3 = 5 or more times).  
• Viral specimen (saliva)  collection,  storage and shipping (refer section 7.7  for more details).  
• Refer “Schedule of Activities” table for additional information on activities and whether they are 
the responsibility  of subjects and /or study team.   
 
9.2.3 Treatment  Day 10 
In addition to procedures described in 9.2.2, the following procedures will be performe d at the in-person 
follow- up visit on Day 10.  
• Assess for AEs   
• Review and a ssess COVID -19 signs and symptoms  
• Document all current medications, including medications over the counter and herbal medic ations  
• Document subject’s status as an outpatient, subsequently hospitalized, or died  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 41 of 63 • Perform clinical assessment and review reported vital signs ( oral temperature , heart rate  and 
oxygen saturation)  
• Collect blood sample for below listed blood  tests:  
o CBC with differential , Electrolytes, BUN, Creatinine, Random Blood Serum Glucose, 
AST, ALT, Bilirubin, uric acid, SARS -CoV2 IgG, IL -6, IL -10, ESR, CRP, D -Dimer, 
ferritin. (CRP = C -reactive protein, IL -6 = Interleukin -6, IL -10 = Interleukin -10, CBC = 
Complete Blood Count).  
 
9.2.4 Post Treatment Days (Day 1 4 to Day 28)  
The following procedures will be performed at all follow -up visits  (post-t reatment days), expected to be 
done remotely , unless otherwise noted, on Day 14, 17, 21, 24, and 28 : 
• Assess for AEs   
• Review and a ssess COVID -19 signs and symptoms  
• Document all current medications, including medications over the counter  and herbal medications  
• Document subject ’s status as an outpatient, subsequently hospitalized, or died  
• Perform clinical assessment and review reported vital signs  (oral temperature , heart rate  and 
oxygen saturation)  
• The study team will be reviewing the data reported by subject to ensure compliance,  accuracy and 
completeness on days 1, 3, 5, 7, 9, 10, 14, 17, 21, 24, and 28.  
• Once the subject meets the primary efficacy endpoint, the subject is not required to c ontinue the 
self-assessment and reporting of COVID -19 symptoms. However, the study team, during the 
remote patient  visits will evaluate and report the severity of COVID -19 associated symptoms as 
per the set frequency mentioned in the Schedule of Activities, under study staff responsib ility.  
 
9.2.5 Final Study Visit (Non -hospitalized Subject s) (Day 28)  
The following procedures will be performed at the final post treatment visit (remote patient visit) : 
• Assess for AEs 
• Document all current medications, including medications over the counter  and herbal medications  
• Document subject’s status as an outpatient, subsequently hospitalized, or died  
• Perform clinical assessment to evaluate for increased severity of COVID -19 related symptoms 
• Pregnancy t est for women of child -bearing potential  
 
9.2.5 Early Termination/Hospitalization     
All subject s have the right to withdraw from study participation at any time during the study. If,  for 
whatever reason, a subject  withdraws from the study  or is hospitalized, an Early Termination Visit will be 
performed. 
The following procedures will be performed at the Early Termination Visit:  
• Assess for adverse events   
• Document all current medications, including medications over the counter and herbal medic ations  
• Perform clinical assessment (as deemed feasible if hospitalized)  
• Evaluate for increased sev erity of COVID -19 related disease   
• Pregnancy Test for women of child -bearing potential  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 42 of 63  
If clinical evaluation is deemed not feasible due to subject  condition, the study t eam to collect Early 
Termination Visit data and attempt to collect Day 21 and Day 28 data and AE assessment for those subjects 
who are hospitalized and deemed off study . 
 
9.2.6 S afety and Other Assessments  
For S tudy procedures and evaluations to be done as part of the study to monitor safety and support the 
understanding of the study intervention’s safety  refer to  Section of Schedule of Activities and Section of 
Study Assessments.  
 
9.3 A dverse Events and S erious A dverse Events  
Adverse event data will be summarized for all subject s from the date of informed consent . Site -reported 
serious adverse events and unexpected adverse drug reactions will be summarized as subject -based counts 
and percentages by AE category , MedDRA system  organ class and preferred term.  In addition, subject  
listings will be provided for seriou s, unexpected, and unanticipated adverse reactions. Any adverse events 
leading to discontinuation of study drug or death will also be listed for all subject s.  
9.3.1 Definition of Adverse Event (AE)  
An AE is defined as any unanticipated medical occurrence regardless to relationship of the investigative 
arm of the trial. An AE can be any unintended sign, lab abnormality, symptom, or disease a ssociated with 
the trial. Any abnormality that presents during a medical test are to be defin ed as an AE if it produce s 
clinical signs and/or symptoms, requires intervention, or deemed clinically si gnificant by the Investigator.  
 
9.3.2 Specific AEs to record  
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will  be utilized for AE 
reporting the following study- specific AEs: 
• Cough 
• Dyspnea 
• Hypoxia 
• Nausea  
• Vomiting  
• Abdominal pain  
• Pruritus 
• Loss of appetite  
• Dizziness  
• Skin rash  
 
9.3.3 Definition of Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered "serious" if, in the view of the Inves tigator, it results 
in any of the following outcomes:  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 43 of 63 • Death  
• A life -threatening AE  
• Requires inpatient hospitalization or prolongs existing hospitalization  
• persistent or  significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
• Medically important event by the Investigator  (including any E D visit)  
• Congenital anomaly/birth defect  
Important medical events that may not result in death, be life -threatening, or require hospitalization may 
be considered serious when, based upon appropriate medical judgment, they may jeopardize the s ubject 
and may require medical or surgical intervention  to prevent one of the outcomes listed in this definition.  
 
9.3.4 Definition of Unexpected Adverse Reaction (UAE)  
An adverse reaction, the nature or severity of which is not consistent with the  applicable product 
information (e.g.  Product Information/Summary of  Product Characteristics). This would include any SAE  
on health or safety, any life -threatening problem or death caused by, or associated with a drug; or any 
other unanticipated serious problem associated with a drug that rel ates to the rights, safety, or welfare of 
subjects.  
 
9.3.5 Definition of Adverse Events (AE)  
Adverse event means any untoward medical occurrence associated with the use of an inter vention in 
humans, whether  (or not) considered intervention -related ( ICH E6( R2), Section 1.2 ). 
 
9.3.6 Classification of an Adverse E vent 
9.3.6.1 Severity of Event  
All AEs will be assessed by the study investigator using the CTCAE V. 5.0 . Investigator or qualified 
designee will assess the severity of AEs using the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;  
intervention not indicated.  
• Grade 2 :   Moderate; minimal, local or noninvasive intervention indicated  
• Grade 3 : Severe or medically significant but not immediately life -threatening; hospitalization or  
prolongation of hospitalization indicated   
• Grade 4:  Life-threatening consequences; urgent intervention indicated.  
• Grade 5  Death related to AE.  
 
9.3.6.2 Relationshi p to Study Intervention  
Relationship to Study Products : All AEs must have their relationship to study intervention assessed by the 
investigator or qualified designee who examines and evaluates the subject  based on temporal relationship 
and his/her clinical judgment. The degree of certainty about causality will be graded usi ng the categories 
below.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 44 of 63  
Definitely:  
 The relationship of the AE and the drug or the study procedure can be established.  
 
Probably:  
 While a clear relationship to the drug or to the study procedure cannot be 
established, the AE is associated with an expected AE or there is no other medical 
condition or intervention, which could explain the occurrence of such an event.  
 
Possibly:  
 There is no clear relationship between the AE and the drug or study procedure; 
however, one cannot conclude that there is no relationship.  
 
Unrelated:  
 There is no relationship between the AE and the drug or study procedure.  This 
may include but is not limited to the incident being an expected outcome of a 
previously existing or concurrent disease, concomitant medication or procedure 
the subject  experience d. 
 
 
9.3.7 Expectedness  
Study T eam members who are  clinically  qualified  (e.g., a physician , co-Investigator , sub -Investigator) 
will be responsible for determining whether an AE is expected or unexpected. An AE wi ll be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the r isk information 
previously described for the study products. Th is information will be provided to the IRB /IEC , and to any 
relevant governmental agency with regulatory or public health authority.  
 
9.3.8 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an AE or SAE  may come to the attention of study personnel during study visits and 
interviews of a study subject  presenting for medical care . 
 
9.3.9 Capturing AEs  
All AEs including local and systemic reactions not meeting the criteria for SAEs will b e captured on the 
appropriate CRF . Information to be collected includes event description, time of onset, investigator’s 
assessment of severity, relationship to study product (assessed only by those with the  training and authority 
to make a diagnosis), and time of resolution/stabilization of the event. All AEs oc curring while on study 
must be documented appropriately regardless of relationship. All AEs will be follow ed to adequate 
resolution. 
 
9.4 Adverse Event Reporting  
Adverse event data will be summarized for al l subject s in the safety population. Serious adverse events 
and unexpected adverse drug reactions will be summarized as subject -based counts and percentages by 
AE category . In addition, subject  listings will be provided for serious, unexpected, and unantic ipated 
adverse reactions. Any adverse events leading to discontinuation of study drug or death will als o be listed 
for all subject s.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 45 of 63  
9.4.1 Serious Adverse Event Reporting  
Study team member s who are qualified will immediately report any serious adverse event, whether or not  
considered study intervention related, including those listed in the protocol  and must include an 
assessment of whether there is a reasonable possibility that the study intervention caused t he event. Study 
endpoints that are SAEs  must be reported in accordance with the protocol .  Refer Section of Unanticipated 
Problems provides further detail.  
 
9.4.2 Reporting E vents to IRB/IEC   
AEs, SAEs and Unanticipated problems (UPs) will be reported to IRB /IEC . 
 
9.4.3 Events of Special Interest  
N/A 
 
9.4.4 Reporting of Pregnancy  
Favipiravir has the potential for teratogenicity. In nonclinical reproductive and  developmental toxicity 
studies, favipiravir was shown to be teratogenic in multiple animal species (mice, rats, rabbits and 
monkeys). P regnancy status will be collected  at the time of enrollment. Pregnancy testing for women of 
child bearing potential will occur on study days 1, 7 And 28. A ny pregnancy that occurs during study days 
1-28 will be followed, until the end, and report ed to FDA  and other regulatory authorities, wher e required .  
 
9.5 Unanticipated Problems  (UPs) 
9.5.1 Definition of U nanticipated Problems (UP s) 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
subject s or others to include, in general, any incident, experience, or outcome that meets all the following 
criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedure s that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)/ 
Independent Ethics Committee (IEC) approved research protocol and informed consent document; 
and (b) the characteristics of the subject  population being studied;  
• Related or possibly related to participation in the research (“possibly relat ed” means there is a 
reasonable possibility that the  incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places subject s or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 46 of 63 9.5.2 Unanticipated Problem Reporting  
The investigator  will report u nanticipated problems ( UPs) to the reviewing IRB/IEC .  The UP report will 
include the following information:  
1. Protocol identifying information: protocol title and number, PI’s name, and the IRB /IEC  project 
number; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken 
or are proposed in response to the UP. 
 
2. To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
• UPs that are SAEs  will be reported to the IRB /IEC  within 10 working days  of the investigator 
becoming aware of the event.  
• A Study Team evaluation of an UP will be performed with a  report of results of such evaluation 
will be provided to the reviewing IRB /IEC  by the PI within 10 working days .  
 
9.5.3 Reporting Unanticipated Problems to Subject s  
Subject s will be informed about UPs, and study -related results on an individual or aggregate level.  
 
 
10.0 STATISTICAL CONSIDERATIONS   
10.1 Statistical Hypotheses  
The primary efficacy objective of this study is to demonstrate that treatment with favipiravir in subjects with 
COVID -19 and mild -to-moderate symptoms will shorten the time to sustained clinical recovery ("c omponent of the 
clinical outcome").” Primary efficacy endpoint: Time to sustained clinic al recovery, defined as the time (number of 
days) from the start of the study treatment until symptom relief , evaluated from study day 1 onward.  
  
10.2 Sample Size Considerations  
10.2.1 Sample Size Determination: study’s primary endpoint: time to sustained clinical recovery by Study  
Day 2 8 
Group sample sizes of approximately 62 5 in each treatment group ( Favipiravir and placebo)  to get at least 
815 clinical recoveries will achieve sufficient power to detect a clinically  meaningful effect size using a  
two-sided Wilcoxon test at an overall  significance level of 0.05.  
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 47 of 63 10.2.2 Sample Size Justification : study’s p rimary endpoint: time to sustained clinical recovery by Study 
Day 2 8 
A review of the medical literature including descriptive and intervention studies r eveals variation in the 
estimate of ‘median time to symptom alleviation’. There is lack of consistency among stu dies in regard 
to: 1) the definition used for ‘symptom alleviation’, 2) the reference time point (som e use the day of first 
symptoms, the day of first positive PCR test, the day of study enrollment, and the day of hos pitalization, 
3) the length of follow up. To account for the uncertainty surrounding the estimate of  ‘median time to 
symptom alleviation’, we performed a series of intermediate sample size calculations for a variety of likely 
scenarios  with median times to sustained clinical recovery for the control group ranging  from 3 to 15 days 
and median times to sustained clinical recovery for the favipiravir group ranging from -1 to -6 days (when 
possible) as compared to the control group. The worst case of those scenarios was r etained to establish the 
definitive sample size estimation for the trial . 
The definiti ve sample size assessment is based on a group sequential design  with a possibility to stop for 
efficacy and for futility (unbinding rule) at interim, once 45% of the information is obtai ned (i.e. 367  
events ), using Power family (Phi=1.147) alpha and beta spending functions. Assuming proporti onal 
hazards, a median time of 5 days in the control group vs. a median time of 4 days in t he favipiravir group 
(which provide a hazards ratio of 1.25) and controlling for an overall alpha of 5% (two -sided), it is 
estima ted that about 475 participants per group would be required to obtain a total of 815 clinical events  
(defined as clinical recoveries) . This will ensure a power of 85 % to detect a difference between the two 
groups in terms of time to clinical recoveries by Day 28.  
 
The unbinding futility rule uses a Power family beta spending function with Phi=1.147  and the probability 
to stop for futility at interim when there is no difference between  the two groups (i.e. HR=1) is 73 %.  
 
The test for efficacy at interim uses a Power family alpha spending function with Phi=1.147  and if the 
hazard ratio is truly 1.25, the probability to conclud e efficacy at interim is 49 %. 
  
This is to be noted that the futility rule is unbinding and that the recommendations whether or not to st op 
for futility will be done by the Data and Safety Monitoring Board (DSMB) (see secti on 5.5), upon review 
of the safety and efficacy data, and not solely based o n the futility rule.  
10.2.3 Sample Size Determination: Sub- study’s Viral Shedding Endpoint: Time to undetectable viral 
shedding by study day 10 
Group sample sizes of approximately 2 75 subjects in each treatment group (Favipiravir and placebo) in 
order to obtain 112 undetectable viral shedding events will achieve sufficient power to detect a clinically  
and epidemiologically meaningful effect size using a  two-sided Wilcoxon test at a significance level of 
0.05. 
10.2.4 Sample Size Justification:  Sub- study’s Viral Shedding Endpoint: Time to undetectable viral 
shedding by study day 10  
To calculate the requ ired sample size, we used the following assumptions: 1) Follow -up duration per 
patient of 10 days, 2) Alpha of 0.05, 3) Lost to follow up of 0, 4) Exponential survival rates, 5) M edian 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 48 of 63 time to sustained clinical recovery for the control group of 5 days, 6)  Median time to sustained clinical 
recovery for the favipiravir group of 2.9 days.  
In order to  detect as statistically significant difference in the median time to undetectable viral s hedding 
of 5 vs. 2.9 days in the control vs. favipiravir group, respectively (HR = 1.7), it is e stimated that a total 
of about 550 subjects ( 275 per treatment group) in order to obtain 112 clinical events defined as 
undetectable viral shedding events would be required to achieve a power of 80%.  
10.3 Po pulations for Analyses 
• Modified-Intention- to-Treat (mITT) Analysis Dataset includes all randomized subjects who took 
at least one dose of study medication  (excluding subjects who qualified for enrollment based upon 
changes in taste and smell) . Some of these subjects were included on a previous version of the 
protocol when the loss of smell or taste was considered as  one of the symptoms to be alleviated.  
• Modified-Intention- to-Treat  2 (mITT 2) Analysis Dataset includes all randomized subjects who 
took at least one dose of study medication  and report ( in ePRO) sufficient protocol -mandated 
COVID -19 symptoms  (excluding ta ste and smell), defined as 2 or more symptoms worse than mild 
on study day 1 . Some of these subjects were included on a previous version of the protocol when 
the loss of smell or taste was considered as one of the symptoms to be alleviated.  
• Intention- to-Treat (ITT) Analysis Dataset  includes all randomized subjects.  
• Safety Analysis Dataset  includes subjects who took at least  one dose of study intervention.  
• Per-Protocol Analysis Dataset: subset of the subject s in the mITT2 set who took at least 80% of 
study intervention and had no protocol violations that would affect the primary efficacy endpoint.  
Such protocol violations include treatment with high dose steroids, remdesivir, or S ARS -CoV -2 
monoclonal antibodies.  
• Other Datasets  that may be used for sensitivity analyses  
 
10.4 Statistical Analyses : General Approach  
Baseline demographic and clinical characteristics and other results will be summar ized using descriptive 
summary statistics. Data collected in the trial will be summari zed overall and by treatment arm.  
Survival analysis techniques will be used to analyze the time -to-event variables. Failure curves will be 
constructed for time to positive event using Kaplan -Meier estimates. Time to sustained clinical recovery 
will be com pared using a Gehan Wilcoxon test  which gives more weight to early events . Time to a 
negative event (such as time to death, time to hospitalization) will be compared using t he Log-rank test 
for comparison of survival distributions.  Summary tables for safety and efficacy endpoints will include 
event rates (Kaplan -Meier estimates of event rates), relative risk, confidence interval for the relat ive risk, 
the difference in means/rates, the confidence interval for difference in means/rates , and the p -value.  
For categorical variables, results within each arm will be summarized with subject  counts, percentages, 
and 95% confidence intervals. The differences between the two treatment arms wil l be summarized with 
the difference in percentages and the asymptotic 95% confidence interval for the dif ference of two 
percentages.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 49 of 63  
10.5 Analysis of the Primary Efficacy Endpoint(s)  
For the primary efficacy endpoint,  time to sustained clinical recovery  from study day 1 onward will be 
compared using a Gehan  Wilcoxon test.  
The primary analysis of the primary efficacy endpoint will be based on the Modified Intent to Treat 
Population (mITT) , defined as any subject randomized into the study and took at least on dose of study 
medication  (excluding subjects who qualified for enrollment based upon changes in taste and smell) .  
Additional primary efficacy endpoint analyses will also be performed using  the mITT,  mITT2, and the 
Per Protocol populations . Every effort will be made to ensure that subjects are followed until 
hospi talization, death , or 28 days post treatment start , whichever happens first .  Subjects who were 
hospitalized or died will be assumed to have not met the primary endpoint in the primary analysis.   
 
10.6 Analysis of the Key Secondary Endpoint(s)  
Proportion of subjects with COVID -19 progression will be presented with counts and percentage. 
Significance among group will be evaluated using Chi-s quare test or fisher test as applicable . The 
corresponding confidence interval for the difference in propor tions will be calculated.  
Viral shedding sub -study ( time in number of days to negative conversion of detectable SARS -CoV -2 viral  
RNA to undetectable viral RNA  in RT -PCR assays of saliva, from start of study treatment to date of last 
viral assessment ) will be analyzed using time -to event methods . 
All secondary endpoint analyses will be performed for the mITT , mITT2  and PP populations .   
Adjustment for multiple te sting will be performed to control the overall type 1 error to no more than 5% 
for the interim and final analysis on the primary efficacy endpoint.  
Moreover, for labeling purposes, a hierarchical approach will be used to control the ove rall type 1 error to  
≤ 5% for the primary and key secondary endpoints. The order of testing wi ll be:  
1. Clinical recovery  
2. Broad progression (key secondary endpoint)  
3. Narrow progression (key secondary endpoint)  
Statistical significance cannot be claimed if the parameter on top of the parameter being tested did not 
reach statistical significance. For example, if clinical recovery was not statis tically significant at final 
analysis, the other parameters will not be considered as having reached statistical  significance (no matter 
the results obtained). If clinical recovery reaches statistical significance at final  analysis and Broad 
progression (key secondary endpoint) does not, the remaining parameters will not be considered a s 
having reached statistical significance and so on.  
10.6.1  Additional Secondary Efficacy Analysis  
The additional secondary endpoint of time to negative conversion of positive SARS -CoV -2 (viral 
culture assays of saliva) will be analyzed as described in the statistical analysis plan (SAP  version 3.1 ). 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 50 of 63 The additional secondary endpoint analys es will be performed for the mITT , mITT2,  and PP 
populations. 
10.7 Safety Analyses  
Adverse event data will be summarized by treatment group for subject s in the safety population. Safety 
will be evaluated by presenting summaries of treatment emergent AEs by system organ class and preferred 
term. Drug related TEAEs, discontinuation of study  medication due to TEAEs and all SAEs will also be 
summarized.  
In addition, subject  listings wi ll be provided for serious, unexpected, and unanticipated adverse reactions. 
Any adverse events leading to discontinuation of study drug or death will also be listed for all  subject s. 
 
10.8 Other prespecified analyses  
10.8.1 Baseline Descriptive Statistics  
Demographic characteristics and medical history, adverse events, COVID -19 disease signs and symptoms 
and treatment compliance will be summarized and compared between treatment groups.  The details of the 
statistical analyses are included in the S tatistical Analysis Plan  (SAP 3.1) . 
 
10.8.2 Planned Interim Analyses  
The DSMB will also review the results of the first interim analysis for futility and ef ficacy  once 45 % of 
the clinical events (i.e. 367 clinical rec overies) are obtained and once 45 % of the patients are recruited.  
The nominal alpha of 0.02 and of 0.0369  at the time of interim and final analysis, respec tively. A p -value 
less than 0.02 (interim) or 0.0369  (final) will be considered to be statistically significant . 
Futility will be conclu ded at interim on the primary efficacy endpoint if Z -value is smaller than 0.58964 
(i.e. p -value is larger than 0.6389) . 
 
10.8.3 Sub- Group Analyses  
1) Status at enrollment defined as Seronegative  (negative IgG ) vs. S eropositive ( positive IgG ). 
2) Age at enrollment: Age ≥ 50 years vs. Age <50 years  and Age ≥ 60 years vs. Age <60 years . 
3) Time from first positive SARS -CoV -2 test to enrolment (<2 days from their first positive COVID 
test vs. >2 days).  
4) Risk-status of COVID -19 progression (high risk vs. others). High -risk for COVID -19 progression 
is defined as patients who meet at least one of the following criteria:   1) Overweight (BMI ≥ 25), 
2) Chronic kidney disease , 3) Diabetes  Mellitus,  4) Weakened immune system,  5) Currently 
receiving immunosuppressive treatment , 6) ≥65 years of age , 7) Pregnancy, 8) Cardiovascular 
disease/hypertension, 9) Chronic lung disease, 10) Sickle cell disease, 11) Neurode velopmental 
disorders, 12) Medical -related t echnological dependence   
5) Ethnicity (Hispanic vs. non -Hispanic).  
6) Magnitude of symptoms at enrol lment (high, defined as having a minimum of 4 symptoms at a 
level of moderate or severe on study day 1 vs. low, defined as having <4 moderate or severe 
symptoms on study day 1).  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 51 of 63 7) Status of receiving SARS -CoV -2 monoclonal antibodies treatment after study enrolment (Yes, 
No).  
8) Status of study -drug adherence (drug adherence >80% defined as: the subject took at least 72 
study- drug pills as documented in ePRO and/or EDC  vs. ≤ 80%). For calculation purposes: day 1 
dose 1 and dose 2 are 9 pills each, all other study doses are 4 pills.  
. Detailed analysis will be described in SAP.  
9) Level of highest RNA load on study day 1 or 2 or 3: high versus vs. all other and very high versus al l other. 
High and very high RNA loads are defined as RNA load of >1,000 or >10,000, respectively.  
10) Type of SARS -CoV-2 variant: Alpha (B.1.1.7), Beta (B.1.351, B.1.351.2, B.1.351.3), Delta 
(B.1.617.2, AY.1, AY.2, AY.3), or Gamma (P.1, P.1.1, P. 1.2).  
11) Status of C -reactive Protein level (abnormally elevated vs. normal) at baseline.  
12) Status of D -dimer level (abnormally elevated vs. normal) at baseline.  
13) Status of C -reactive Protein level and D -dimer (both are abnormally elevated vs. other) at baselin e. 
 
10.8.4 Tabulation of Individual subject  Data   
N/A 
 
10.8.5 Sensitivity Analysis  
All subjects with an initial recovery who later relapsed within the 28 -day period labeled as not meeting 
the primary endpoint.  Detailed list of all sensitivity analys es is described in the SAP 3.1.   
 
10.9 Exploratory Analyses  
Exploratory endpoints are related to proportion of subjects and will be presented with counts and 
percentage. Significance among group will be evaluated using Chi-S quare test or Fisher test as applicable . 
The corresponding confidence interval for the difference in proportions will be calculat ed. 
A detailed description of all statistical analyses is described  in the SAP 3.1. 
 
11.0 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
11.1 Regulatory, Ethical , and Study Oversight Considerations.    
11.1.1 Informed Consent Process  
11.1.1.1   Consent/assent and Other Informational Documents Provided to subject s 
Consent describing in detail the study intervention, study procedures, and risks will be  provided to the 
subject  and documentation of informed consent will be  required prior to  administering study intervention s.   
 
11.1.1.2  Consent Procedures and Documentation  
Informed consent (IC) is a process that is initiated prior to the individual’s agreeing to participate in the  
study and continues throughout the individual’s study participation. The investigator will explai n the 
research study to the subject  and answer any questions that may arise.  The explanation will be provided 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 52 of 63 in terms suited to the subject ’s comprehension of the purposes, procedures, and potential risks of the study 
and of their rights as research subject s.  Potential subject s will have the opportunity to ask question s. The 
subject s will have the opportunity to discuss the study with their family or surrogates or think about i t 
prior to agreeing to participate. They will be informed that participation is voluntary and that they may 
withdraw from the study at any time, without prejudice. The rights and welfare of the subject s will be 
protecte d by emphasizing to them that the quality of their medical care will not be adversely af fected if 
they decline to participate in this study.  
 
FDA regulations generally require that the informed consent of a trial subject  be documented by the use 
of a written consent form that has been approved by the IRB /IEC  and signed and dated by the subject at 
the time of consent (21 CFR 50.27(a)). Considering COVID -19 infection control measures, if the 
technology is available, current FDA guidance suggests that electronic methods of obtaining informed 
consent should be considered as follows:  
• To ensure that subject s are approached in a consistent fashion, a standard process should be used 
that will accomplish the following:  
1. Identification of who is on the call or telemedicine visit  
2. Review of the I nformed Consent with the subject  by the investigator (or their designee) 
and response to any questions the subject  may have  
3. Confirmation by the witness that the subject ’s questions have been answered  
4. Confirmation by the investigator that the subject  is willing to participate in the trial and 
sign the informed consent  document while the witness is listening on the phone  
5. Verbal confirmation by the subject  that they would like to participate in the trial and that 
they have signed and dated the informed consent document that is in their possession.  
 
• If the signed informed consent document cannot be collected from  the subject ’s location and 
included in the study records, FDA considers the following option acceptable to provide 
documentation that the subject  signed the informed consent document:  
1. A dated attestation by the witness who participated in the call and by the investigato r that 
the subject  confirmed that they agreed to participate in the study and signed the informed 
consent. 
For this study involving subject s with COVID -19 positivity, in accordance with FDA guidance, t he 
following steps will be performed while obtaining the IC by phone or telehealth video chat from the 
Subject.  
• Purpose of the study and the potential risks/benefits of the use of the Investigational A gent 
favipiravir in the treatment of confirm ed COVID -19 infection will discussed in detail by the 
principal investigator or qualified designee (PI/ designee)  with the subject prior to obtaining the 
IC.  Opportunity to review the ICF (informed consent form) prior to or during the discussion wi ll 
be provided .  Adequate time for discussion between the PI  or qualified designee  will be gi ven to 
the potential subject .  After review of the IC, any questions that the potential subject  have will be 
addressed during or after review of the IC.  
 
• Availability and/or possibility of other potential treatment options will be discusse d with the 
subject . 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 53 of 63  
• A second member of the study team will be present on the phone or video chat during the entire 
discussion. The witness will ask  the p otential subject  if they underst and the contents of the 
discussion and if they ha ve any questions  to address.  The subject  will be informed that they can 
ask questions at any time during the trial.  
 
• The PI  or qualified designee  will sign the ICF along with the witness. Copies of the signed f orm 
will be placed i n the subject ’s medical record  
 
• This document will be placed into the electronic medical record  and electronically signed, and 
time stamped by the investigator. In de -identified form, it will be the study source document for 
documenting the process of obtaining ICF.   A copy of the electronically signed consent (signed by 
the witness and investigator) is either emailed  or sent by US Mail . 
 
11.1.2  Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is suf ficient reasonable cause.  
Written notification, documenting the reason for study suspension or termination, will be  provided b y the 
suspending or terminating party to study subject s, investigator, funding agency, and regulatory authorities.  
If the study is prematurely terminated or suspended, the  Principal Investigator ( PI) will promptly inform 
study subject s and the Instituti onal Review Board ( IRB)/ Independent Ethics Committee  (IEC)  for the 
termination or suspension.  Study subject s will be contacted, as applicable, and be informed of changes to 
study visit schedule.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subject s 
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to protocol requirements  
• Data that are no t sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
The s tudy may resume once concerns about safety, protocol compliance, and data quality are addressed  
and the IRB/IEC . 
 
11.1.3 Confidentiality and Privacy  
Subject  confidentiality and privacy is strictly held in trust by the participating investigator s, their staff, 
and the sponsor(s) and their interventions. This confidentiality is extended to cover te sting of biological 
samples in addition to the clinical information relating to subject s. Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict c onfidence. No information 
concerning the study, or the data will be released to an y unauthorized third party without prior written 
approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.   The use of the telemedicine  
video platform  will include subject  instruction on using the platform in a private setting or with a family 
member/ significant other via Facetime as described in the Study Intervention.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 54 of 63 Representatives of the Institutional Review Board ( IRB)/ Independent Ethics Committee  (IEC)  or 
regulatory agencies may inspect all documents and records required to be maintained by the  investigator, 
including but not limited to, medical and pharmacy records for the subject s in this study.  The clinical 
study site will permit access to such records.  
The study subject ’s contact information will be securely stored for internal use during the st udy. At the 
end of the study, all records will continue to be kept in a secure location for as long a per iod as dictated 
by the reviewi ng IRB /IEC  and Institution al policies.  
The Principal Investigator will be responsible to ensure the study is conducted in ac cordance with the 
protocol, Good Clinical Practice (GCP), applicable regulatory requirement s, and that the data recorded is 
valid. To achieve this objective, the study will be continuously monitored, and the study conduct r eviewed 
on a weekly basis by the Study T eam.  
Monitoring will be conducted to ensure that the rights and well -being of human subject s are protected, 
that the reported trial data are accurate, complete, and verifiable, and that the conduct of the trial follows 
the currently approved protocol/amendment(s), with GCP, and with applicable regulat ory requirement(s).  
 
A Clinical Monitoring Plan will be created by the Study T eam and will describe in detail the personnel 
who will conduct the monitoring, at what frequency monitoring will be done, at what level of  detail 
monitoring will be performed, and the distribution of monitoring reports.  
 
11.1.4 Future Use of Stored Specimens and Data  
The collection of personal subject  information will be limited to the amount necessary to achieve the aims 
of the research, so that no unneeded sensitive information is being collected.  
Data from the EDC will be exported into Excel or SAS file format (pass word protected), which will then 
be used for data analysis.  Only de -identified, not including the subject ’s contact or identifying information 
data will be used for data analysis.  
 
11.1.6 S afety Oversight 
In addition to the Principal Investigator’s responsibility for overall study oversight, safety  oversight will 
be under the direction of a Data and Safety Monitoring Board (DSMB) composed of individual s with the 
appropriate e xpertise.  Members of the DSMB are  independent from the study conduct and  free of conflict 
of interest.   The DSMB will operate  under the rules of an approved charter written and reviewed at the 
organizational meeting of the DSMB. After the organization meeting, the DSMB will meet as outlined in 
the charter. The final meeting scheduled will be outlined in the charter.  The DSMB wil l also review the 
results of the interim analysis for efficacy described in section of “Statistical  Considerations ”. Stopping 
rules for safety and efficacy will be specified in the charter.  
 
11.2 Clinical Monitoring 
Clinical monitoring will be  conducted to ensure that the rights and well -being of trial subject s are 
protected, that the reported trial data are accurate, complete, and verifiable, and that  the conduct of the 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 55 of 63 trial is in compliance with the currently  approved protocol/amendment(s), with International Conference 
on Harmoni zation Good Clinical Practice  (ICH GCP ), and with applicable regulatory requirement(s).  
 
11.2.1 Q uality Assurance and Quality Control 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated . Any missing data or data anomalies will be 
communicated to study PI or designee for resolution.  
Following written Standard Operating Procedures ( SOPs ), the PI and study team  will verify that the 
clinical trial is conducted, and data are generated,  and biological specimens are collected , documented 
(recorded), and reported in compliance with the protocol, International Conference on Harmonization  
Good Clinical Practice (ICH GCP ), and applicable regulatory requirements (e.g., Good Laboratory 
Practices (GLP), Good Manufacturing Practices ( GMP)).  
The investigational site will provide direct access to all source data/docume nts, and reports for the purpose 
of monitoring , auditing and inspection by local and regulatory authorities.  
 
11.3 Data H andling  and Record  Keeping  
11.3.1 Data Collection and Management Responsibilities  
Data collection is the responsibility of the Study S taff under the supervision of the Investigator . The 
Investigator is responsible for ensuring the accuracy, completeness, legibilit y, and t imeliness of the data 
reported.  All source documents will be  completed in a neat, legible manner to ensure accurate 
interpretation of data.   
Any h ardcopies of study visit worksheets  will be provided for use as source document  worksheets for 
recording dat a for each subject  enrolled in the study.  Data recorded in the electronic case report form 
(eCRF ) derived from study source documents will be consistent with the data recorded on the source 
documents .  
Clinical data AEs, concomitant medications  and any other data collected from subject s will b e entered 
into a 21 CFR Part 11 ready data capture system .  The data system includes  an audit trail, password 
protection and internal quality checks, such as automatic range checks, to ident ify data that appear 
inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly from the source documents.  
 
11.3.2 Study Records Retention  
Data from the study will be maintained for two (2) years after the date the investigati on is completed, 
terminated or until the records are no longer required to support the protocol, whichever da te is later.  
Custody of the records may be transferred. Subject records and data are eligible for inspection and/or 
copying by applicable regulatory authorities.  
 
11.4 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Internationa l Conference on 
Harmonization  Good C linical Practice ( ICH GCP) , or Manual of Procedures ( MOP ) requirements. The 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 56 of 63 noncompliance may be either on the part of the subject , the Investigator, or the Study Team. As a result 
of deviations, corrective a ctions are to be developed by the site and implemented promptly.  
These practices are consistent with ICH GCP :  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
Protocol deviations will be summarized by type of deviation and treatment group. Protocol devia tion 
summaries will be subject based . 
 
11.5 Publication and Data Sharing Policy  
The preparation and submittal for publication of manuscripts containing the study results s hall be in 
accordance with a process determined by mutual written agreement among the study Sponsor a nd 
participating institution s.  The publication or presentation of any study results shall comply with all 
applicable privacy laws, including, but not limited to, the Health Insurance Port ability and Accountability 
Act of 1996.  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Info rmation Submission rule. 
As such, this trial will be registered at ClinicalTrials.gov, and results in formation from this trial wil l be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish res ults in peer -reviewed 
journals. 
 
11.6 C onflict of  Interest  Policy 
The independence of this study from any actual or perceived influence, such as by the pharmaceut ical 
industry, is critical.  Therefore , any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and manage d. Furthermore, 
persons who have a perceived conflict of interest will be required to have su ch conflicts managed in a way 
that is appropriate to their participation in the design and conduct of this trial.  The study leadership in 
conjunction has established policies and procedures for all study group members to disclose  all conflicts 
of interest  and will establish a mechanism for the management of all reported dualities of in terest.  
 
11.7 Additional Considerations  
N/A 
 
12.0 Abbreviations 
AE Adverse Event  
ANCOVA  Analysis of Covariance  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 57 of 63 COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF  Case Report Form  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data Safety Monitoring Board  
DRE  Disease -Related Event  
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
EDC  Electronic Data Capture  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
FFR Federal Financial Report  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
GWAS  Genome- Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
IP Investigational Product  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption 
IND Investigational New Drug Application  
IRB Institutional  Review Board  
IEC Independent Ethics Committee  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention- To-Treat  
IWRS  Interactive Web Randomization System  
LSMEANS  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NCT  National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SOA  Schedule of Activities  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 58 of 63 SOC  System Organ Class  
SOP Standard Operating Procedure  
UP Unanticipated Problem  
US United States  
 
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 59 of 63 13.0 Protocol Amendment History  
The table below is intended to capture key changes made between protocol version 5.0 and 5.1  
Version 5.0 Version 5.1  Rationale 
Site-Subject Remote Visits on Days 1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 14, 17, 21, 24 and 28  
 
 
 
It is the site responsibility to ensure patients 
are properly trained on the ePRO requirements 
and assist the subjects with completing the 
ePRO diary during the Day 1 visit. Subject 
interactions will happen on Days 2 through 12, 
as well as 14, 17, 21, 24, and 28. During the 
site and subject interactions, the site staff will 
review the ePRO content for completeness and 
will work with the subject to ensure complete 
data entry. This includes reviewing each 
COVID -19 symptom for severity, 
temperature, O2 saturat ion, review of AEs, 
concomitant medications, IP compliance and 
saliva sampling compliance (when applicable). 
Beyond Study Day 12, in the case that subject 
has not reported on ePRO on a day that a 
subject visit is not scheduled, the study team 
will call the  subject (unscheduled visit) and 
ensure that the subject enters the missing 
information during the phone call. However, if 
the ePRO system is unavailable or not 
accessible by the subject for any reason, then 
the subject should record their information on 
the paper diary for those days. If the subject 
used paper diary, during the next site and 
subject interaction, site staff should complete 
the data entry on behalf of the subject in 
ePRO. The study team will collect the paper 
diary from the subject after the y either meet 
the clinical recovery or the subject reaches 
Day 28.  
 
 Site-Subject Remote Visits on Days 1, 3, 5, 7, 
9, 14, 17, 21, 24 and 28  
 
 
The study team will be reviewing the data 
reported by subject to ensure compliance, 
accuracy and completeness on days 1, 3, 5, 7, 9, 
10, 14, 17, 21, 24, and 28.  Beyond Study Day 
10, once the subject meets the primary efficacy 
endpoint, the subject is not required to continue 
the self -assessment and reporting of COVID -19 
symptoms. However, the study team, during the 
remote patient visits will evaluate and report th e 
severity of COVID -19 associated symptoms as 
per the set frequency mentioned in the table.  
 
 
 
 
 
 
 
 
 
 
 
 
Removed: While collecting adverse events, 
subjects will be asked whether or not  any of 
their adverse events resulted in an emergency 
department (ED) visit.  In cases where this has 
occurred, the date of the visit will be recorded, 
the reason for the visit (i.e. - COVID -19 
associated symptom or not), and the adverse 
event(s) which pro mpted the visit. Because ED 
visits are considered to be a medically -
important event determining in part the 
subject’s COVID progression, ED visits for any 
cause will be documented as SAEs.  
 
  
Change made to address FDA 
concerns related to site -subject 
interactions (protocol  versions 
4.0 and 5.0 have never been 
implemented). The change 
reflects protocol version 3.0 
which was the last version 
implemented during the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The change reflects protocol 
version 3.0 which was the last 
version implemented during the 
study. 
From: 
Primary Efficacy Endpoint:  To: 
Primary Efficacy Endpoint:   
In accordance with FDA 
guidance 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 60 of 63 The endpoint will be considered to have been 
met at the earliest time point from study day 1 
onward at which the subject has reached 
Sustained Alleviation of Symptoms as defined 
by:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified- Intention -to-Treat (mITT) Analysis 
Dataset includes all randomized subjects who 
took at least one dose of study medication and 
report (in ePRO) sufficient protocol -mandated 
COVID -19 symptoms (excluding taste and 
smell), defined as 2 or more symptoms worse 
than mild on study day 1 . Some of these 
subjects were included on a previous version of 
the protocol when the loss of smell or taste was 
considered as one of the symptoms to be 
alleviated.  
 
 
 
 
 
 
 
 
 
 
 
 
 The endpoint will be considered to have been 
met at the earliest time point from study day 3 
onward at which the subject has reached 
Sustained Alleviation of Symptoms as defined 
by: 
 
Added:  
(COVID- 19 symptoms can be missing for 1 of 
the first two sustainability days but not for the 
last day of sustainability)  
 
Change in the Viral Load threshold from 100 
RNA copies to 15 RNA copies (the 
detectability threshold)  
. 
 
 
 
mITT Population changed to include all 
randomized and treated subjects regardless of 
their Day 1 ePRO entries.  
 
The original mITT population as described in 
Protocols V4.0 and V5.0 is now named 
mITT2. mITT2 is used for exploratory and 
sensitivity analyses.  
 
 
 
 
Addition of exploratory and sensitivity 
analyses.  
 
 
 
 
 
Slight change in the definition of the sub -group 
that is at high risk for COVID -19 progression   
 
 
 
 
In accordance with FDA 
guidance 
 
 
 
 
In accordance with FDA 
guidance 
 
 
 
 
 
 
In accordance with FDA 
guidance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To reflect the current definition 
used by FDA   
 
 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 61 of 63  
14.0 REFERENCES  
1. WHO Director -General's statement on IHR Emergency Committee on Novel Coronavirus (2019 -
nCoV), 30 January 2020  
2. FIJIFILM Toyama Toyama Chemical Co. Ltd AVIGAN (Favipiravir) Package Insert for Japan (7th 
version). April 2019  
3. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patien ts with COVID -19 
[published online ahead of print, 2020 Jun 25]. SN Compr Clin Med. 2020;1 -8. doi:10.1007/s42 399-
020-00363-4 
4. BCCDC. COVID -19 vulnerable populations. British Columbia Centre for Disease Control. 2020. 
[Accessed April 18, 2020, http://www.bccdc.ca/health -info/diseases-conditions/covid-19/vulnerable-
populations]. 
5. Sleeman K, Mishi, V, Deyde V, F uruta Y, Klimov A, Gubareva L, 2010. In vitro antiviral activity of 
favipiravir (T -705) against drug -resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents 
Chemother. 54, 2517 –24. 
6. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVI D-19: An open -label 
control study. Engineering. 2020. doi: https://doi.org/10.1016/j.eng.2020.03.007 . 
7. Chen C, huang J,  cheng Z, et al. favipiravir versus arbidol for COVID -19: A randomized clinical trial. 
medRxiv. 2020. [preprint, doi:10.1101/2020.03.17.20037432].  
8. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T -705), a novel 
viral RNA po lymerase inhibitor. Antiviral Res. 2013;100(2):446 -454 
9. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the r ecently emerged 
novel coronavirus (2019 -nCoV) in vitro. Cell Res. 2020;30(3):269 -271 
10. Shiraki K, Daikoku T. Favipiravir, an anti -influenza drug against life -threatening RNA virus 
infections. Pharmacol Ther. 2020:107512  
11. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T -705), a novel 
viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446-454 
12. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the r ecently emerged 
novel coronavirus (2019 -nCoV) in vitro. Cell Res. 2020;30(3):269 -271 
13. Shiraki K, Daikoku T. Favipiravir, an anti -influenza drug ag ainst life -threatening RNA virus 
infections. Pharmacol Ther. 2020:107512  
14.  Pharmaceuticals and Medical Devices Agency (2014)  Report on the Deliberation Res ults - 
Favipiravir (JAN*), accessible at: https://www.pmda.go.jp/files/000210319.pdf   
15.  Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the r ecently emerged 
novel coronavirus (2019 -nCoV) in vitro. Cell Res. 2020;30(3):269 -271 
16.  Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz -Fontela C, Gunther S. Successful treatment of 
advanced ebola virus infection with T -705 (favipiravir) in a small animal model. Antiviral Res. 
2014;105:17-21 
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 62 of 63 17. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post -exposure efficacy of oral 
T-705 (favipiravir) against inhalational ebola virus infection in a mouse model. Antivira l Res. 
2014;104:153-155 
18. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T -705), a novel 
viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446 -454 
19. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravi r for ebola virus 
disease (the JIKI trial): A historically controlled, single -arm proof -of-concept trial in guinea. PLoS 
Med. 2016;13(3):e1001967.  
20. Bai CQ, Mu JS, Kargbo D, et al. Clinical and virological characteristics of ebol a virus disease patients 
treated with favipiravir (T -705)- sierra leone, 2014. Clin Infect Dis. 2016;63(10):1288 -1294. 
21. Jacobs M, Aarons E, Bhagani S, et al. Post -exposure prophylaxis against ebola virus disease with 
experimental antiviral agents: A case -series of health -care workers. Lancet Infect Dis. 
2015;15(11):1300-1304. 
22. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Cur r Opin 
Infect Dis. 2019;32(2):176 -186. doi:10.1097/QCO.0000000000000532.  
23. Ministry of Health, Labour and Welfare. Report on the deliberation results. .AV IGAN (favipiravir) 
Review Report from Japanese Health Authority 2014.  
24. Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir f or Ebola Virus 
Disease (the JIKI Trial): A Historically Controlled, Single -Arm Proof -of-Concept Trial in Guinea 
[published correction appears in PLoS Med. 2016 Apr;13(4):e1002 009.  
25. Dortenzio, Eric [corrected to D’Ortenzio, Eric]] [published correct ion appears in PLoS Med. 2016 
Jun;13(6):e1002066]. PLoS Med. 2016;13(3):e1001967. Published 2016 Mar 1. 
doi:10.1371/journal.pmed.1001967. 
26. Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola -Infected patients of 
the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis . 2017;11(2):e0005389. 
Published 2017 Feb 23. doi:10.1371/journal.pntd.0005389.  
27.  To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior o ropharyngeal saliva 
samples and serum antibody responses during infection by SARS -CoV -2: an observational cohort 
study. Lancet Infect Dis 2020.  
28. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of 
novel coronavirus (SARS -CoV -2). Science 2020;368:489 -93. 
29. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel c oronavirus in 
Wuhan, China. Lancet 2020;395:497-506. 
30. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patie nts With 2019 Novel 
Coronavirus- Infected Pneumonia in Wuhan, China. JAMA 2020.  
31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with 
COVID -19 in Wuhan, China: a retrospective cohort study. Lancet 2020.  
32. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients  with SARS -CoV -2 
pneumonia in Wuhan, China: a single -centered, retrospective , observational study. Lancet Respir 
Med 2020.  
 
PRESECO  Confidential Appili Therapeutics Inc.  
Protocol: ATI0220  Version: 5.1 Dated: 02-November-2021 Page 63 of 63 33. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-presenta tion/ 
34. https://www.fda.gov/media/141192/download   
35. https://www.fda.gov/media/141541/download   
36. McGeer, Allison at all, University of Toronto (unpublished data. Enclosed) 
Preseco Protocol V5.1_2021-11-03_Clean_FINA
L
Final Audit Report 2021-11-04
Created: 2021-11-04
By: Prasann Bavaniya (pbavaniya@appilitherapeutics.com)
Status: Signed
Transaction ID: CBJCHBCAABAAmaHHNSQ4On97W9ksmORifgjCwkkvMyyq
"Preseco Protocol V5.1_2021-11-03_Clean_FINAL" History
Document created by Prasann Bavaniya (pbavaniya@appilitherapeutics.com)
2021-11-04 - 3:29:57 AM GMT- IP address: 99.227.48.85
Document emailed to Yoav Golan (ygolan@appilitherapeutics.com) for signature
2021-11-04 - 3:30:57 AM GMT
Email viewed by Yoav Golan (ygolan@appilitherapeutics.com)
2021-11-04 - 3:31:10 AM GMT- IP address: 75.69.182.51
Document e-signed by Yoav Golan (ygolan@appilitherapeutics.com)
Signature Date: 2021-11-04 - 3:35:05 AM GMT - Time Source: server- IP address: 75.69.182.51
Agreement completed.
2021-11-04 - 3:35:05 AM GMT
